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1FOREWORD
In 2016, UNAIDS published a landmark report on HIV and drugs. That report—
Do no harm: health, human rights and people who use drugs—showed how the 
world was failing to protect the health and human rights of people who use drugs, 
and it provided a road map for countries to reduce the harms that are associated 
with drug use, and to turn around their drug-related HIV epidemics. 
Three years later, this report, Health, rights and drugs: harm reduction, 
decriminalization and zero discrimination for people who use drugs, shows that 
people who use drugs are still being left behind. New HIV infections among 
adults worldwide declined by 14% between 2011 and 2017, but there has been no 
decrease in the annual number of new HIV infections among people who inject 
drugs. This is unacceptable: people who use drugs have rights, and too often these 
rights are being denied.
In 2016, I wrote that “Business as usual is clearly getting us nowhere” and called 
for countries to learn lessons from those that had reversed their HIV epidemics 
among people who inject drugs. Despite this, too many countries are failing 
to learn those lessons and carrying on with business as usual. As a result of 
the current global approach, persistently high rates of HIV, viral hepatitis and 
tuberculosis continue among people who inject drugs.  
We know what works. There is compelling and comprehensive evidence that 
harm reduction—including opioid substitution therapy and needle–syringe 
programmes—improves the health of people who inject drugs. It is safe and cost-
effective. Additionally, when people who use drugs have access to harm reduction 
services, they are more likely to take an HIV test, and if found to be living with 
HIV, enrol in and adhere to HIV treatment. 
Decriminalization of drug use and possession for personal use reduces the stigma 
and discrimination that hampers access to health care, harm reduction and legal 
services. People who use drugs need support, not incarceration.
I’ve seen what works: an opioid substitution programme in Minsk, Belarus, 
that helps people dependent on opioids live with dignity; and a health centre 
in Saskatoon, Canada, that provides sterile injecting equipment so that people 
who inject drugs can prevent the spread of HIV, viral hepatitis and other blood-
borne infections. Such enlightened and effective programmes should be available 
wherever and whenever there is a need. Sadly, they are the exceptions, and policies 
that criminalize and marginalize people who use drugs are too often the rule. 
The time is overdue to revisit and refocus the global approach to drug policy, 
putting public health and human rights at the centre. I’ve said it before and I will 
say it again: if we are to end AIDS by 2030, we can’t leave anyone behind. And that 
includes people who use drugs.
Michel Sidibé
UNAIDS Executive Director
2“AT THE UNITED NATIONS GENERAL ASSEMBLY SPECIAL SESSION ON THE 
WORLD DRUG PROBLEM . . . GOVERNMENTS CAME TOGETHER TO CHART A 
NEW PATH FORWARD THAT IS MORE EFFECTIVE AND HUMANE, AND LEAVES 
NO ONE BEHIND . . .
“IT IS VITAL THAT WE EXAMINE THE EFFECTIVENESS OF THE WAR-ON-DRUGS 
APPROACH AND ITS CONSEQUENCES FOR HUMAN RIGHTS. DESPITE THE 
RISKS AND CHALLENGES INHERENT IN TACKLING THIS GLOBAL PROBLEM, 
I HOPE AND BELIEVE WE ARE ON THE RIGHT PATH, AND THAT, TOGETHER, 
WE CAN IMPLEMENT A COORDINATED, BALANCED AND COMPREHENSIVE 
APPROACH THAT LEADS TO SUSTAINABLE SOLUTIONS.”
UNITED NATIONS SECRETARY-GENERAL António Guterres 26 June 2017
INTRODUCTION
People who use drugs have been the 
biggest casualties of the global war 
on drugs. Vilified and criminalized 
for decades, they have been pushed 
to the margins of society, harassed, 
imprisoned, tortured, denied services, 
and in some countries, summarily 
executed. Billions of dollars spent, a 
considerable amount of blood spilt 
and the imprisonment of millions of 
people have failed to reduce either the 
size of the drug trade or the number 
of people who use psychoactive 
substances (1). 
Amid the widespread stigma and 
discrimination, violence and poor 
health faced by people who use 
drugs, people who inject drugs are 
beset by persistently high rates of 
HIV. While the incidence of HIV 
infection globally (all ages) declined 
by 25% between 2010 and 2017, HIV 
infections among people who inject 
drugs are rising (Figure 1). Outside 
of sub-Saharan Africa, people who 
inject drugs and their sexual partners 
account for roughly one quarter of 
all people newly infected with HIV. 
In two regions of the world—eastern 
Europe and central Asia, and the 
Middle East and North Africa—
people who inject drugs accounted 
for more than one third of new 
infections in 2017. Viral hepatitis 
and tuberculosis rates among people 
who use drugs also are high in many 
parts of the world. These preventable 
and treatable diseases, combined 
with overdose deaths that are equally 
preventable, are claiming hundreds of 
thousands of lives each year.
This is a problem that has a clear 
solution: harm reduction. Study 
after study has demonstrated that 
comprehensive harm reduction 
services—including needle–syringe 
programmes, drug dependence 
treatment, overdose prevention with 
naloxone, and testing and treatment 
for HIV, tuberculosis, and hepatitis 
B and C—reduce the incidence of 
blood-borne infections, problem 
drug use, overdose deaths and 
other harms. Countries that have 
successfully scaled up harm reduction 
have experienced steep declines in 
HIV infections among people who 
inject drugs. 
Armed with this overwhelming 
evidence, grass-roots organizations 
of people who use drugs, 
harm reduction and human 
rights advocates, and allied 
nongovernmental organizations 
have played a leading advocacy role 
on harm reduction. Civil society 
organizations also are instrumental 
in the delivery of harm reduction 
services, often through trusted peer 
outreach workers.
In 2016, the United Nations (UN) 
General Assembly held a Special 
Session on the World Drug Problem. 
Amid growing calls for a people-
3centred, public health and human 
rights-based approach to drug use, 
UN Member States agreed to an 
outcome document that took an 
important step forward: it called 
for effective public health measures 
to improve health outcomes for 
people who use drugs, including 
programmes that reduce the impact 
of the harms sometimes associated 
with drug use. The outcome 
document also underlined the need 
to fully respect the human rights 
and fundamental freedoms of people 
who use drugs, and it called on 
countries to consider alternatives to 
punishment for drug offences (3).
A few months after the 2016 Special 
Session, the UN General Assembly 
convened a high-level meeting on the 
global HIV epidemic. The meeting 
concluded with the 2016 Political 
Declaration on Ending AIDS that 
acknowledged people who inject 
drugs as a key population at high risk 
of HIV infection who face stigma 
and discrimination and restrictive 
laws that hamper their access to 
HIV services (4). The 2016 Political 
Declaration on Ending AIDS contains 
a commitment to “saturating areas 
with high HIV incidence with a 
combination of tailored prevention 
interventions,” including harm 
reduction, and it encourages UN 
Member States to reach 90% of those 
at risk of HIV infection with these 
services (4). 
In 2017, the International Narcotics 
Control Board (INCB) also called 
for the abolition of the death penalty 
for drug-related offenses, stressing 
the importance of human rights 
and public health principles in drug 
control (5, 6).
However, change within countries 
has been slow. Three years after the 
2016 Special Session, needle–syringe 
distribution and opioid substitution 
Figure 1. Comparison of incidence of HIV, people who inject drugs and total population (all ages), 
global, 2011–2017
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Note: The scales of the vertical axes in each graph are different. HIV incidence is considerably higher among people who inject drugs compared to 
the general population. Plausibility bounds for incidence among people who inject drugs are adopted from the new infections’ calculated bounds 
rather than directly estimated. 
Source: UNAIDS 2018 estimates.
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therapy coverage remain low in most 
of the 51 countries that have reported 
data to UNAIDS in recent years.  
Just three high-income countries 
—Austria, Luxembourg and 
Norway—reported that they had 
achieved UN-recommended levels 
of coverage for these programmes 
(Figure 2). Those three countries 
are home to less than 1% of the 
global population of people who 
inject drugs. A recent systematic 
review of published harm reduction 
programme and survey data similarly 
found that less than 1% of people who 
inject drugs globally live in countries 
with sufficient access to these critical 
harm reduction services (7). 
This low coverage is perpetuated by 
low investment. Only a handful of 
low- and middle-income countries 
have reported expenditures to 
UNAIDS that are sufficient to meet 
the needs of people who inject drugs. 
Domestic financing is particularly 
4Figure 2. Coverage of needle–syringe programmes and opioid substitution therapy, by country, 
last year available (2013–2017)
Source: UNAIDS Global AIDS Monitoring, 2013–2017.
Pe
o
p
le
 w
ho
 in
je
ct
 d
ru
g
s 
re
ce
iv
in
g
 o
p
io
id
 s
ub
st
itu
tio
n 
th
er
ap
y 
(%
)
Needles–syringes distributed per year per person who injects drugs
Malta
Malaysia
France
Spain
Portugal Ireland
GreeceCyprus
Viet Nam
United Republic 
  of Tanzania Ukraine
North Macedonia
Thailand
Tajikistan
Slovenia
Seychelles
Serbia
Romania
Republic of
Moldova
Norway
Nepal
Myanmar
Morocco
Mauritius
Luxembourg
Lithuania
Latvia
Kyrgyzstan
Kenya
Kazakhstan
Italy
Iran (Islamic 
Republic of)
Indonesia
India
Georgia
Finland
Estonia
Dominican Republic
Czechia
Cambodia
Bulgaria
Bosnia and Herzegovina
Belgium
Belarus
Bangladesh
Azerbaijan
Austria
Armenia
Albania
Afghanistan
0 50 100 150 200 250 300 350 400 450 500
0
10
20
30
40
50
60
70
80
90
100
0
20
“MANY POLICY-MAKERS CONTINUE TO THINK THAT HARM REDUCTION 
ENCOURAGES DRUG USE, AND [THAT] OPIOID SUBSTITUTION 
TREATMENT IS ABOUT REPLACING ONE DRUG WITH ANOTHER.  
IT MEANS THAT MORE ADVOCACY WORK SHOULD BE DONE. AS CIVIL 
SOCIETY, WE SEE IT AS OUR PREROGATIVE TO WORK WITH THE 
GOVERNMENTS AND CONVINCE THEM THAT HARM REDUCTION WORKS.”
Elie Aaraj, Middle East and North Asia Harm Reduction Network (2)
5use—that are proven to have 
negative health outcomes and that 
counter established public health 
evidence (21).
The Declaration and Plan of Action 
on International Cooperation 
towards an Integrated and Balanced 
Strategy to Counter the World 
Drug Problem, adopted at the 
2009 high-level segment of the 
Commission on Narcotic Drugs, 
set targets for countries to achieve 
by 2019, including a target to 
“eliminate or reduce significantly and 
measurably” the supply and demand 
for these drugs (22). As this deadline 
approaches, data from the United 
Nations Office on Drugs and Crime 
(UNODC) show that the global war 
on drugs—and the punitive response 
to drug use—has failed to achieve 
these targets (1). Recognition of 
this failure is growing, and more 
communities, cities and countries 
that are grappling with the realities 
of drug use are embracing harm 
reduction. Meanwhile, much of the 
world continues to wage a war on 
drugs and to turn its back on people 
who use drugs, slowing progress on 
the pledges they made at the UN 
General Assembly in 2016.
As a new chapter begins in the 
response to the world drug problem, 
UNAIDS calls on countries to end 
the divide on drug use. Stronger 
and more specifics commitments 
for a human rights-based, people-
centred and public health approach 
to drug use are needed, and those 
commitments need to be rapidly 
transformed into national and local 
laws, policies, services and support 
that allow people who use drugs to 
live healthy and dignified lives.
low: in 31 countries that reported 
expenditure data to UNAIDS, 71% 
of the spending for HIV services for 
people who use drugs was financed 
by external donors (8–10). 
Even when services are available, 
criminalization of drug use and harsh 
punishments discourage their uptake. 
Punishments can include lengthy 
prison sentences, heavy fines and, in 
some cases, even the death penalty. 
An estimated one in five persons in 
prison globally are incarcerated for 
drug-related offenses; approximately 
80% of these cases are related to 
possession alone (11, 12). People in 
detention often have less access to 
harm reduction services and face 
greater risk of HIV, tuberculosis and 
viral hepatitis transmission, as well as 
other health risks. Intersecting forms 
of discrimination and vulnerability 
related to gender, age and race have 
different impacts on people who 
use drugs. 
Thirty-five countries retain the death 
penalty for drug-related offences, and 
the Philippines has seen thousands 
of extrajudicial executions of people 
who use drugs since a national 
crackdown began in 2016 (11, 13). 
Some countries have removed 
criminal laws on drug possession 
and use, but they instead use 
administrative laws to detain people 
who inject drugs in compulsory drug 
detention centres that have been 
linked to torture, forced labour and 
other abuses (11). 
In sharp contrast, decriminalization 
of drug use and possession for 
personal use has been shown to 
facilitate the provision, access and 
uptake of health and harm reduction 
services. Czechia, the Netherlands, 
Portugal and Switzerland are 
among a handful of countries that 
have decriminalized drug use and 
possession for personal use and that 
have also financially invested in harm 
reduction. The number of new HIV 
diagnoses among people who inject 
drugs in these countries is low (14).
Multiple UN and regional human 
rights mechanisms—including the 
UN Special Rapporteur on the right 
to the highest attainable standard 
of health, the UN Committee on 
Economic, Social and Cultural 
Rights, the African Commission on 
Human and Peoples’ Rights, and 
the Office of the United Nations 
High Commissioner for Human 
Rights (OHCHR)—have found that 
criminalization of activities related 
to personal drug use can negatively 
affect a person’s health and well-
being, and they have recommended 
decriminalization of activities related 
to personal drug use (15–19). In 
advance of the 2016 UN General 
Assembly Special Session on the 
World Drug Problem, four UN 
Special Rapporteurs joined the Chair 
of the Committee on the Rights 
of the Child to issue a statement 
describing the current international 
drug control regime as “excessively 
punitive” and calling for human 
rights obligations to be better 
integrated into the international drug 
control regime (20).1
In 2017, 12 UN entities issued 
a joint statement on stigma and 
discrimination within health-care 
settings that called on countries to 
review and repeal punitive laws—
including the criminalization of 
drug use and possession for personal 
1. The four Special Rapporteurs were Mr Juan E Méndez (Special Rapporteur on torture and other cruel, inhuman or degrading treatment or punishment), Mr Christof 
Heyns (Special Rapporteur on extrajudicial, summary or arbitrary executions), Mr Seong-Phil Hong (Chair-Rapporteur of the UN Working Group on Arbitrary 
Detention), and Mr Dainius Pûras (Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health). 
They joined Benyam Dawit Mezmur, Chair of the UN Committee on the Rights of the Child.
RECOMMENDATIONS
The overarching purpose of drug control should be first and foremost 
to ensure the health, well-being and security of individuals, while also 
respecting their agency and human rights at all times. As UN Member 
States reflect on what has occurred in the 10 years since the 2009 Political 
Declaration and Plan of Action on International Cooperation towards an 
Integrated and Balanced Strategy to Counter the World Drug Problem, 
UNAIDS reiterates its call for a public health and human rights approach to 
drug use, calling on countries to adopt the following recommendations.
Implement harm reduction services
Fully implement comprehensive harm reduction and HIV services—
including needle–syringe programmes, opioid substitution therapy, 
naloxone and safe consumption rooms—on a scale that can be easily, 
voluntarily and confidentially accessed by all people who use drugs, 
including within prisons and other closed settings.
Ensure that all people who are drug dependent have access to 
noncoercive and evidence-informed drug dependence treatment that 
is consistent with international human rights standards. All forms of 
compulsory drug and HIV testing and compulsory drug treatment should 
be replaced with voluntary schemes. The use of compulsory detention 
centres for people who use drugs should cease, and existing centres 
should be closed.
Ensure widespread availability of naloxone, including injectable and 
noninjectable (nasal) forms, through community-based distribution 
of this life-saving public health measure. All people likely to witness 
an overdose—such as health workers, first responders, prison staff, 
enforcement officials, family members and peers—should have access to 
naloxone to enable timely and effective prevention of deaths from opioid 
overdose among people who use drugs.
Access to health-care services
Ensure that all people who use drugs have access to prevention, testing 
and life-saving treatment for HIV, tuberculosis, viral hepatitis and sexually 
transmitted infections (STIs). 
Ensure adequate availability of and appropriate access to opioids for 
medical use to reduce pain and suffering. 
Facilitate access for people who use drugs to HIV, sexual and reproductive 
health, and other health services through an integrated, people-centred 
approach that is gender-responsive and youth-friendly.
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Ensure that universal health coverage systems are structured in a way 
that makes services accessible and acceptable to people who use drugs, 
including both integrated and stand-alone services, as needed.
Human rights, dignity and the rule of law
Protect and promote the human rights of people who use drugs 
by treating them with dignity, providing equal access to health and 
social services, and by decriminalizing drug use/consumption and the 
possession, purchase and cultivation of drugs for personal use. 
Where drugs remain illegal, adapt and reform laws to ensure that people 
who use drugs have access to justice (including legal services) and do 
not face punitive or coercive sanctions for personal use, and that policing 
measures encourage people to access harm reduction and health 
services voluntarily. Ensure the principle of proportionality is applied for 
drug-related crimes, and put in place public health-based alternatives to 
incarceration, administrative penalties and other forms of corrective action.
Ending stigma and discrimination
Take action to eliminate the multiple intersecting forms of stigma and 
discrimination experienced by people who use drugs, including while 
accessing health, legal, education, employment and social protection 
services, or when interacting with law enforcement.
People-centred approach
Include, support, fund and empower communities and civil society 
organizations—including organizations and networks of people who use 
drugs—in all aspects of the design, implementation, and monitoring and 
evaluation of drug policies and programmes, as well as in the design and 
delivery of HIV, health and social protection services. 
Ensure an enabling legal environment for civil society organizations of and 
for people who use drugs so they can operate without fear of intimidation, 
threat, harassment or reprisal.
Ensure use of social contracting modalities for engaging allied 
nongovernmental organizations for the delivery of community-led and 
community-based harm reduction services.
Investment
Undertake a rebalancing of investments in drug control to ensure 
sufficient funding for human rights programmes and health services, 
including the comprehensive package of harm reduction and HIV services, 
community-led responses and social enablers.
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9One in 18 adults use drugs
An estimated 275 million people 
worldwide—5.6% of the adult 
population—used drugs at least once 
in 2016 (1). Cannabis is the most 
widely used recreational drug.2 An 
estimated 19.4 million people used 
opioids, many of whom injected their 
drugs (Figure 3). Some non-opioid 
drugs—such as amphetamines, 
barbiturates, cocaine and 
methamphetamines—are sometimes 
consumed via injection. 
Injecting drugs carries a high risk of 
HIV and viral hepatitis transmission 
if sterile injecting equipment is 
not easily accessible and injecting 
equipment is shared among users. In 
2016, more than half of people who 
inject drugs were living with hepatitis 
C, and one in eight were living 
with HIV.
The prevalence of injecting drug use 
varies by region and country. For 
example, the eastern Europe and 
central Asia region was home to 
21% of the world’s people who inject 
drugs (aged 15–64 years) in 2016, 
despite having only 4% of the global 
population within that age range 
(Figure 4). Similarly, western and 
central Europe and North America 
had a greater share of people who 
inject drugs than their share of the 
global population (2–4).
Almost half of all people who injected 
drugs worldwide in 2016 lived in just 
three countries: China, the Russian 
Federation and the United States 
of America. Although these three 
countries together account for just 
27% of the global population (aged 
15–64 years), they are home to 45% of 
the world’s people who inject drugs—
an estimated 4.8 million people (1, 2). 
Drug control efforts have little 
impact 
The billions of dollars spent each year 
on efforts to reduce the supply of 
and demand for illicit drugs have not 
resulted in a reduction of the overall 
number of people who use drugs. 
The United Nations Office on Drugs 
and Crime (UNODC) estimates 
suggest that the number of people 
who use drugs each year may have 
risen between 2006 and 2016, largely 
due to increased use of cannabis 
(Figure 5). However, this increase 
PEOPLE 
WHO USE 
DRUGS: A 
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UNDER 
ATTACK
Activists for people who use drugs and sex workers at their office in Kyiv, Ukraine.  
Credit: Global Fund/Efrem Lukatsky.
2. Not including alcohol and tobacco, which are not included in the estimate.
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Figure 3. Population size of people who use drugs, global, 2016
Among the 275 million 
people globally who used 
drugs at least once in 2016
19.4 million used opioids and
10.6 million injected  
drugs, among whom  
1.26 million were living with HIV.HIV+
Source: World drug report 2018. Vienna: UNODC; 2019.
Figure 4. Number of people who inject drugs (aged 15–64 years), by region, 2016
  Asia and the Pacific
  Western and central Europe and North America
  Eastern Europe and central Asia
  Latin America and the Caribbean
  Middle East and North Africa
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ChinaRussian
Federation
Source: World drug report 2018. Vienna: UNODC; 2019.
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falls within the uncertainty bounds 
of the estimates and cannot be 
considered conclusive. Meanwhile, 
the number of people with drug use 
disorders has stayed roughly the same 
over the decade.3
UNODC and UNAIDS estimates 
suggest that the global number of 
people who inject drugs may be 
slowly declining, but this trend also 
lies within the uncertainty bounds of 
the estimates. 
HIV is on the rise among 
people who inject drugs
The incidence of HIV infection 
among people who inject drugs 
appears to have risen over the past 
decade, from 1.2% [1.0–1.3%] in 
2011 to 1.4% [1.2–1.5%] in 2017. 
This is in contrast to the overall 
trend worldwide, which shows a 
25% decline in HIV incidence (all 
ages) between 2010 and 2017.4 The 
decreasing size of the population 
of people who inject drugs and the 
increasing incidence of HIV within 
that population have contributed 
to an increase in the percentage of 
people who inject drugs who are 
living with HIV (up from 11.4% in 
2011 to 12.5% in 2016) (1, 5). 
Hepatitis B and C and 
tuberculosis are also 
widespread
Hepatitis C virus is more resilient 
than HIV, and it is capable of 
surviving on drug preparation and 
injecting equipment for several 
days to weeks (6). Hepatitis C virus 
is thus easier to transmit when 
injecting equipment is shared, and 
when people who inject drugs do 
not have access to needle–syringe 
programmes, hepatitis C infection 
is often more common than HIV 
infection. Globally, an estimated 
51.9% of people who inject drugs had 
hepatitis C infection in 2016; among 
the 71 million people with hepatitis 
C globally in 2016, an estimated 8% 
were people who inject drugs (7, 8). 
An estimated 7% of people living with 
HIV who inject drugs have hepatitis 
B (8). As more and more people 
living with HIV access antiretroviral 
therapy and thus live longer, 
coinfection with chronic hepatitis B
is associated with accelerated 
progression of cirrhosis and higher 
rates of liver-related mortality (8). 
People who use drugs tend to 
have higher rates of tuberculosis 
and higher prevalence of latent 
tuberculosis infection than others 
(9). This is in part due to high 
incarceration rates of people who use 
drugs: the risk of tuberculosis disease 
3. UNODC defines people with drug use disorders as a subset of people who use drugs. People with drug use disorders need treatment, health and social care, and 
rehabilitation. Under the UNODC definition, the harmful use of substances and dependence are features of drug use disorders.
4. UNAIDS does not calculate estimates of HIV prevalence and incidence among noninjecting drug users. Data are not routinely collected for this population in the Global 
AIDS Monitoring system or the HIV estimates process.
Figure 5. Global trends in estimated number of people who use drugs (aged 15–64 years), 
2006–2016
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Source: World drug report 2018. Vienna: UNODC; 2019.
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in prisons is on average 23 times 
higher than the risk in the general 
population (10). Among people living 
with HIV, those who inject drugs 
have a twofold to sixfold greater risk 
of developing tuberculosis than those 
who do not (10).
Prevalence of multidrug resistant 
tuberculosis is also high among 
people living with HIV who use 
drugs (9). In eastern Europe, access 
to treatment for multidrug resistant 
tuberculosis is low; as a result, 
mortality is high (11, 12). 
Women
Drug use is more common among 
men, with women accounting for just 
one in three people who use drugs 
and one in five people who inject 
drugs (1). However, women who use 
drugs face special health risks.
Although few countries report 
sex-disaggregated data to UNAIDS 
on people who inject drugs, the 
majority of publicly available data 
suggest that women who inject drugs 
have a greater vulnerability than 
men to HIV, hepatitis C and other 
blood-borne infections (1). In 16 of 
the 21 countries that reported such 
data since 2013, women who inject 
drugs were more likely to be living 
with HIV than their male peers. In 
Germany, Uganda and Uzbekistan, 
HIV prevalence among women who 
inject drugs was almost twice as high 
as among their male peers (Figure 6).
Women also appear to be 
disproportionately affected by the 
criminalization of drugs, with higher 
rates of convictions and incarceration 
for drug-related offences than men. 
This has drawn the attention and 
  Male        Female
Source: UNAIDS Global AIDS Monitoring, 2013–2017.
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Figure 6. HIV prevalence among people who inject drugs by sex, last year available (2013–2017)
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condemnation of the UN Committee 
on the Elimination of Discrimination 
against Women (CEDAW) (13, 14). 
CEDAW, along with the UN Working 
Group on Arbitrary Detention, has 
noted with concern the increasing 
number of women incarcerated 
for drug-related crimes, as well 
as the disproportionate rates of 
incarceration of poor and otherwise 
marginalized women. Those who 
are incarcerated often lack access to 
gender-sensitive health and harm 
reduction services (15, 16).
Young people
Drug use among young people is 
generally more common than among 
older people, with substance use 
often peaking at 18 to 25 years (1). 
Early life adversity is associated with 
an increased risk of substance use 
and dependence (18). For example, 
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Women who use drugs in conflict and emergency settings face complex 
challenges. 
The armed conflict in eastern Ukraine, which started in 2014, has 
had a significant negative impact on people who use drugs. The 
nongovernmental organization Svitanok Club has conducted special 
surveys to understand the needs of this highly stigmatized population. 
Many women who use drugs migrated to other parts of Ukraine to avoid 
the conflict, but they returned when they were unable to find housing or 
employment, a challenge made worse by stigma and discrimination. 
“They now live in extreme poverty, and simply have no money to pay for 
rent,” says Svetlana Moroz of Svitanok Club. The women that Moroz has 
interviewed are often homeless. “They returned back to their homeland, 
but many still lost their homes.” Many rely on other family members, 
leaving them vulnerable to intimate partner violence. 
Moroz says that the women she studied—many of whom are survivors of 
abuse, including kidnappings and beatings—need specialized services. 
“They need psychological and psychotherapeutic support, and none of 
this is available. No one works with them on their traumatic experience 
of torture or other violence” (17).
the risk of methamphetamine use 
is higher among young people 
who grow up in an unstable family 
environment, and many studies have 
observed high levels of substance 
use—including injecting drug use—
among street children (1).
Only a handful of countries 
have reported to UNAIDS 
age-disaggregated estimates of HIV 
prevalence among people who inject 
drugs. These data generally show 
that HIV prevalence is lower among 
younger people who inject drugs 
(under 25 years of age). Fewer years 
spent at higher risk of HIV infection 
(e.g., sharing injecting equipment) 
compared to older people who 
inject drugs is likely a factor in this 
difference. 
Key populations
As well as people who inject drugs, 
key populations at high risk of HIV 
infection include sex workers, gay 
men and other men who have sex 
with men, transgender women and 
prisoners. 
Many people within these key 
populations face multiple risks. 
Because same-sex sexual behaviour, 
sex work, and in some cases, diverse 
gender identities, are criminalized in 
many countries, lesbian, gay, bisexual, 
transgender and intersex (LGBTI) 
people and sex workers who use 
drugs all face additional vulnerability 
to police harassment and misconduct 
and to violence in detention (19, 20). 
Stigma and discrimination, abuse or 
violence linked to sexual orientation, 
gender identity and sex work are 
also widely reported in health-care 
settings (21). These multiple risks 
are likely to lead to higher HIV 
prevalence than among those who 
have only one type of risk (22–26).
Sex workers who use drugs face 
multiple forms of violence, 
violations of privacy, and stigma 
and discrimination (27). Chemsex—
intentional sex under the influence of 
various psychoactive drugs—is on the 
rise among gay men and other men 
who have sex with men (28, 29). The 
drugs used in chemsex are reported 
to reduce inhibitions and intensify 
pleasure, and chemsex may involve 
unprotected sexual activity with 
multiple partners. For these reasons, 
it is associated with increased rates of 
STIs, including HIV and hepatitis C 
(30–32). 
Violence
People who use drugs face an elevated 
risk of many forms of violence. For 
example, more than half of people 
who inject drugs surveyed in Pakistan 
reported that they had experienced 
physical violence in the previous 
12 months (33). In the Philippines, 
a national campaign to crack down 
on the drug trade has resulted in 
thousands of extrajudicial killings 
(34, 35). 
CASE STUDY:  
MEETING THE NEEDS  
OF WOMEN IN CONFLICT 
SETTINGS
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Women who use drugs report 
particularly high rates of both 
gender-based violence and police 
abuse (36). A 2016 study in 
Kyrgyzstan found that 60% of the 
women who use drugs surveyed in 
the study reported surviving physical 
or sexual violence in the past year 
(36). Similarly, a study in Indonesia 
found that more than 50% of women 
who use drugs reported physical 
or sexual violence from their male 
partners in the previous year (37). 
Sixty per cent of women in the same 
study who reported contact with law 
enforcement also reported verbal 
abuse by police, while 27% reported 
physical abuse and 5% reported 
sexual abuse. Violence perpetrated by 
police tends to be underreported due 
to the risk of retaliation. 
Violence of all kinds exacerbates the 
existing risk of transmission of HIV 
and other blood-borne infections and 
STIs, and it can negatively affect the 
ability of women to negotiate safer 
sex and safer drug use (38).
Mortality
Stigma and discrimination, violence 
and low access to health and harm 
reduction services together drive 
higher rates of mortality among 
people who use drugs. Globally, 
there were 450 000 deaths directly or 
indirectly related to drug use in 2015 
(1). The majority of these deaths were 
caused by overdose or were related 
to infections of HIV and hepatitis C. 
These were deaths that could have 
been prevented by harm reduction.
Opioid-related deaths are on the 
rise in many parts of the world. In 
the United States, deaths related 
to drug use increased sixfold from 
1980 to 2014 (39). Drug overdose 
Figure 7. Age-adjusted drug overdose death rates, United States, 1999–2017
Notes: Deaths are classified using the International Classification of Diseases, 10th Revision. Drug poisoning (overdose) deaths are 
identified using underlying cause of death codes X40–X44, X60–X64, X85, and Y10–Y14. 
Sources: NCHS, National Vital Statistics System, Mortality. Data Brief 329. Drug overdose deaths in the United States, 1999–2017. 
Data table for Figure 7. Age-adjusted drug overdose death rates: United States, 1999–2017 (https://www.cdc.gov/nchs/data/
databriefs/db329_tables-508.pdf, accessed 25 February 2019).
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deaths have recently skyrocketed in 
the United States, climbing by 16% 
annually since 2014, reaching 70 237 
deaths in 2017 (Figure 7) (40). In 
2017, the lifetime odds of dying from 
an accidental opioid overdose in the 
United States exceeded for the first 
time the lifetime risk of dying in a 
motor vehicle crash (Figure 8). 
Canada is also experiencing an 
ongoing public health crisis of opioid 
overdoses. There were more than 
9000 opioid-related deaths between 
January 2016 and June 2018, and 72% 
of accidental overdose deaths in 2017 
involved either fentanyl or fentanyl 
analogues (41). In the European 
Union, Norway and Turkey, opioid 
overdose deaths increased 34% in five 
years, from 6800 in 2012 to 9100 in 
2016 (Figure 9) (42).
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Figure 8. Lifetime odds of dying due to injury, selected causes, United States, 2017 
Source: National Center for Health Statistics. Mortality data for 2017 are compiled from data provided by the 57 vital statistics jurisdictions through 
the Vital Statistics Cooperative Program. Deaths are classified on the basis of the 10th Revision of The international classification of diseases (ICD-10), 
which became effective in 1999. See: https://injuryfacts.nsc.org/all-injuries/preventable-death-overview/odds-of-dying/data-details/.
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Figure 9. Drug-induced mortality, European Union member states, Norway and Turkey, 
2009–2016
Source: Statistical bulletin 2018–overdose deaths. In: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) [website]. Lisbon: EEMCDDA 
(http://www.emcdda.europa.eu/data/stats2018/drd).
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The provision of harm reduction 
services has consistently reduced 
morbidity and mortality among 
people who use drugs.
The foundation of a rights-based 
public health approach to drug use, 
harm reduction is a set of principles 
and an evidence-informed package 
of services and policies that seeks 
to reduce the health, social and 
economic harms of drug use. 
Harm reduction is grounded in the 
recognition that not all persons who 
use drugs are able or willing to stop 
using drugs. The principles of harm 
reduction include trust, inclusivity, 
non-judgmental attitudes, flexibility 
to adapt to the needs of clients, 
and the active participation of the 
community of people who use drugs 
in planning, implementation and 
evaluation. Harm reduction services 
should also respect such fundamental 
rights as privacy, bodily integrity, 
dignity, due process and freedom 
from arbitrary detention.
A comprehensive approach
The World Health Organization 
(WHO),United Nations Office on 
Drugs and Crime (UNODC) and 
UNAIDS recommend delivering a 
comprehensive set of harm reduction 
services to people who inject drugs, 
including the following: 
 Needle–syringe programmes. 
 Drug dependence treatment, 
including opioid substitution 
therapy. 
 HIV testing and counselling. 
 Antiretroviral therapy. 
 Prevention and treatment of 
sexually transmitted infections 
(STIs). 
 Condom programmes for people 
who inject drugs and their sexual 
partners. 
 Targeted information, education 
and communication for people 
who inject drugs and their sexual 
partners. 
 Diagnosis, treatment and 
vaccination for viral hepatitis. 
 Prevention, diagnosis and 
treatment of tuberculosis (1).
WHO has also recommended 
opioid overdose management with 
community distribution of naloxone 
for overdose prevention. Pre-exposure 
prophylaxis (PrEP) is not explicitly 
recommended for people who inject 
HARM
REDUCTION:
LINKING
HUMAN RIGHTS 
AND PUBLIC 
HEALTH
“PEOPLE WHO INJECT DRUGS CAN BE  
FOUND IN ALL SEGMENTS OF THE SOCIETY. 
THEY ARE A PRIORITY TARGET OF SENEGAL’S 
NEW HIV/AIDS STRATEGY.”
 
Safiatou Thiam, Executive Secretary of the Senegal National Council for the 
Fight against AIDS (9)
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drugs but should be available on 
demand to them (2). Evidence also 
suggests that safe consumption sites 
offer many benefits (3). 
Needle–syringe programmes 
Evidence
Needle–syringe programmes reduce 
the probability of transmission of 
HIV and other blood-borne diseases 
by lowering the rates of sharing of 
injecting equipment among people 
who inject drugs (4, 5). 
Coverage
To prevent HIV transmission, WHO 
recommends distributing 200 needles 
and syringes per person who injects 
drugs each year. In 2018, 86 countries 
had at least one operational needle–
syringe programme (6). However, 
of 68 countries that have reported 
programme data to UNAIDS since 
2013, only 14 have distributed the 
recommended amount. Global 
programme coverage has remained 
largely static for the past seven years 
(see Annex 1). 
Maximizing impact
Well-designed needle–syringe 
programmes help clients access a 
range of related services, including 
drug dependence treatment, health 
care, and legal and social services. 
Programme managers should also 
understand the types of drugs that 
are injected, how they are injected 
and the type of injecting equipment 
that is preferred. Providing low 
dead-space syringes helps decrease 
the risk of transmission of HIV 
among people who inject drugs 
who continue to share injecting 
equipment (7). However, if the 
injecting equipment provided does 
not fit local preferences, uptake may 
be low. WHO recommends offering a 
range of needle–syringe types to meet 
diverse needs (1, 8).
Drug dependence treatment, 
including opioid substitution 
therapy
Evidence
Evidence-informed forms of drug 
dependence treatment, such as 
opioid substitution therapy using 
methadone or buprenorphine, curb 
the use of opioid drugs. They greatly 
reduce the risk of HIV and hepatitis 
C acquisition and reduce the risk of 
overdose (10–13). Opioid substitution 
Figure 10. A comprehensive approach to HIV and other harms associated with 
drug use
Source: Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. 
Geneva: WHO, UNODC, UNAIDS; 2012; and Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. 
2016 update. Geneva: WHO; 2016.
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therapy has also been shown to 
substantially increase HIV treatment 
enrollment, treatment adherence and 
viral suppression among people living 
with HIV who inject drugs (14).
Following the rapid escalation of 
overdose-related deaths in three cities 
in Croatia between 2001 and 2007, 
the introduction and scale-up of 
opioid substitution therapy coincided 
with a reduction in overdose 
mortality rates by an average of 8% 
annually between 2007 and 2015 
(Figure 11) (15). 
There is also demand for effective 
treatment and support for 
dependence on noninjecting 
drugs and nonopioid drugs. 
Opioid substitution therapy may 
be effective for pharmaceutical 
opioid dependence (16). Effective 
substitution treatment for dependence 
on stimulants, including cocaine, is 
in the pipeline; treatment trials using 
psychostimulants appear promising 
and deserve further study (17). 
Coverage
United Nations (UN) guidelines 
recommend 40% coverage of opioid 
substitution therapy (10). While 
there is uncertainty in the estimates 
of opioid users in many countries, 
in most countries that have reported 
data to UNAIDS, the coverage of 
opioid substitution therapy among 
people who inject drugs is lower 
than desirable (see Annex 2). 
Harm Reduction International has 
documented the existence of opioid 
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Figure 11. Age-adjusted rates of overdose-related mortality, observed and modelled, 
Croatia, 2001–2015
Source: Handanagic S, Bozicevic I, Sekerija M, Rutherford GW, Begovac J. Overdose mortality rates in Croatia and factors associated with 
self-reported drug overdose among persons who inject drugs in three Croatian cities. Int J Drug Policy. 2019;64:95–102.
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Opioid substitution therapy 
introduced in 2007
substitution therapy programmes 
in 86 countries (6). A number 
of countries are scaling up these 
services: of the 23 countries that 
reported coverage data to UNAIDS 
in the last three years, 12 showed 
significant increases in the number 
of people enrolled. Afghanistan and 
Georgia reported large percentage 
increases, albeit from very low levels 
of coverage. Malaysia added more 
than 58 000 patients over a three-year 
period.
Maximizing impact
Only one in nine people who use 
drugs develop drug use disorders 
such as drug dependence (83). 
Regardless, many people who use 
drugs are forced to enter compulsory 
drug dependence programmes, 
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including in cases where treatment 
is not clinically indicated. This is a 
violation of their rights, and WHO 
and UNODC have stressed that drug 
dependence treatment should not be 
coerced (18). 
Additionally, relapse into drug use 
should not be grounds for expelling 
individuals from drug dependence 
treatment. Drug dependence is a 
chronic health condition that often 
requires long-term and continued 
treatment. Those affected may remain 
vulnerable to relapse for a lifetime. 
Patients who relapse need continued 
medical attention and support. 
User fees for dispensing opioid 
substitution therapy may create 
barriers to accessing and maintaining 
therapy, and governments should 
consider sponsorship of fees, 
reducing fees or eliminating them 
altogether (19–21). The Georgian 
Network of People who use Drugs has 
reported that eliminating user fees 
resulted in a sevenfold increase in 
drug dependence treatment coverage 
in just two years (22). 
HIV testing and treatment
Evidence
UN Member States have committed 
to achieving the 90–90–90 testing and 
treatment targets: to ensure by 2020 
that 90% of people living with HIV 
know their HIV status, 90% of people 
who know their HIV-positive status 
are accessing treatment and 90% of 
people on treatment have suppressed 
viral loads. Antiretroviral therapy 
protects people living with HIV from 
AIDS-related illnesses and greatly 
lowers the risk that they will transmit 
the virus to others.
Coverage
Global progress towards these targets 
has been strong in recent years, but 
people who inject drugs and other 
key populations are often being left 
behind. Among the 13 countries that 
recently reported data to UNAIDS 
on treatment coverage among people 
living with HIV who inject drugs, 
eight stated that treatment coverage 
was lower among people who inject 
drugs than it was among the wider 
population of adults living with HIV 
(Figure 12).
Maximizing impact
It is essential to routinely offer 
voluntary, confidential HIV testing to 
people who use drugs, such as when 
individuals access needle–syringe 
services and drug dependence 
treatment. 
Innovative approaches to reaching key 
populations have also been shown to 
deliver results, although some bring 
risks that must be carefully addressed. 
These innovative approaches include 
community-based testing, self-testing 
and diverse forms of index testing.
All HIV testing should be undertaken 
only with informed consent (28). 
Community-based testing, linked to 
prevention, care and treatment, has 
the potential to reach greater number 
of people than clinic-based HIV 
testing and counselling—particularly 
those unlikely to go to a facility for 
testing, including people who inject 
drugs (2, 29). 
HIV self-testing is a form of testing 
where individuals gather their own 
specimens (oral fluid or blood) to 
perform an HIV test and interpret the 
results in private (30, 31). 
With index testing, a person with 
a confirmed diagnosis refers other 
untested individuals for HIV testing 
and counselling services. Two forms 
of index testing are assisted partner 
notification services and risk network 
tracing. Each comes with benefits and 
risks: 
 Assisted partner notification is 
increasingly used among couples 
Despite the universally-recognized principle that prisoners should enjoy 
the same standards of health care that are available in the community—
and the explicit recognition by governments that health services in 
prisons should ensure continuity of treatment and care, including for drug 
dependence and HIV, tuberculosis and other infectious diseases—harm 
reduction coverage in prisons remains low (23–26). 
In 2017, only seven countries reported to UNAIDS that they had needle–
syringe programmes in prisons, and just 18 reported prison programmes 
for opioid substitution therapy. The actual number may be higher: these 
did not include European Union member states, some of which also offer 
harm reduction in prisons (27).
PRISONS
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in high-prevalence settings. It 
has proven highly effective at 
finding new cases (32). Health-
care workers should plan for 
and address the risk of intimate 
partner violence or social harm 
that may result following partner 
notification (33).  
 Risk network approaches, 
sometimes also referred to as 
“contact tracing,” are widely 
used to reach key populations in 
concentrated epidemics. Using 
such an approach, health-care 
workers ask recently diagnosed 
individuals to refer others in their 
social networks for HIV testing. 
In Tajikistan and Ukraine, this 
approach has helped to efficiently 
find undiagnosed people living 
with HIV (34, 35). Given the risks 
of discrimination, violence and 
arrest, HIV testing programmes 
working with key populations 
should consult with communities 
representing those populations 
before adopting risk network 
approaches to testing, and they 
should take measures to keep 
the personal data of individuals 
confidential.
WHO recommends that countries 
implement high impact interventions 
to prevent and respond to HIV drug 
resistance (36). Integrating harm 
reduction and treatment can help 
to improve treatment adherence 
for people who use drugs, ensuring 
individuals are speedily referred for 
second-line treatment when needed. 
A recent systematic review found that 
providing opioid substitution therapy 
to people living with HIV who 
inject drugs significantly improved 
initiation of (and adherence to) 
antiretroviral therapy: this approach 
had a 45% better chance of patients 
achieving viral suppression (37).
Combination prevention  
of HIV and STIs
Evidence
People who use drugs have multiple 
intersecting needs. Combined 
provision of condoms and lubricants, 
behavioural interventions, and sexual 
and reproductive health information 
and services (including contraception 
and STI testing and treatment) 
have been shown to lower the risk 
of sexual transmission of HIV and 
STIs. Staff of harm reduction services 
should be trained and supported 
to provide counselling for people 
Figure 12. Treatment coverage among all adults living with HIV and among people who inject 
drugs in particular, last year available (2014–2017)
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who use drugs on family planning 
and contraception, and they should 
understand the full range of the 
sexual and reproductive health needs 
and rights of both people who use 
drugs and their partners (38). Tools 
such as the new United Nations 
Population Fund (UNFPA) and 
International Planned Parenthood 
Federation Health, rights and well-
being: a practical tool for HIV and 
sexual and reproductive health and 
rights programmes for young key 
populations in eastern Europe and 
central Asia provides guidance on 
how to provide combined services 
in a manner that meets the needs of 
different populations (39). 
PrEP is one option that enables 
individuals to reduce their HIV 
risk by taking regular doses of 
Malaysia, Philippines and Serbia (see 
Annex 3).
There have been limited efforts to 
provide PrEP to people who use 
drugs. Community attitudes toward 
it vary (40–42). Concerns about 
adherence, cost-effectiveness and 
the potential for coercive use—
and insufficient engagement of 
communities in the development of 
pilot efforts—have all been raised by 
community groups and researchers 
(41, 43–45). Civil society groups 
have also expressed concerns that 
the introduction of PrEP could 
be used as a substitute for other 
harm reduction strategies and 
that a strong focus on PrEP could 
indicate a re-medicalization of HIV 
(44). Any decision about whether 
to include PrEP in harm reduction 
Opioid substitution therapy patient takes methadone at the District Heath Centre of South Tu Liem, Hanoi, Viet Nam. Credit: UNAIDS.
antiretroviral medicines. WHO 
recommends that PrEP be offered 
as an additional prevention choice 
for all people at substantial risk of 
HIV infection (2). However, the 
introduction of PrEP should not 
come at the expense of other proven 
low-cost interventions that reduce 
the health and social consequences of 
drug use. 
Coverage
Condom programmes and behaviour 
change interventions designed 
for the general population are not 
adequately reaching people who 
use drugs. Among the 30 countries 
that have reported relevant data to 
UNAIDS since 2011, condom use 
at last sex among people who inject 
drugs was generally low, and fewer 
than one third did so in Hungary, 
23
programmes should be made only 
with the active consultation and 
engagement of the community of 
people who use drugs, and it should 
take their preferences into account. 
Some national programmes have 
developed specific guidance to assess 
the suitability of PrEP for people who 
inject drugs (46, 47).
Prevention and management 
of viral hepatitis and 
tuberculosis
Evidence
People who use drugs face 
increased risk of tuberculosis 
infection, including a high risk of 
multidrug-resistant tuberculosis. 
WHO recommends a package of 
collaborative tuberculosis/HIV 
activities. Key services include 
tuberculosis preventive treatment, 
such as isoniazid preventive therapy, 
regular screening for early diagnosis 
of tuberculosis, and timely initiation 
of anti-tuberculosis therapy and 
antiretroviral therapy for people living 
with HIV who use drugs (2, 48). 
People who inject drugs face 
additional vulnerability to hepatitis B 
CASE STUDY:  
YOUNG WAVE
Young Wave is youth-led group in Lithuania that provides harm reduction 
services at music festivals and night clubs. Young Wave volunteers join 
public gatherings of young people to share information about safe drug 
use, condoms, water (to prevent dehydration and overheating), straws 
for snorting drugs (to prevent transmission of viral hepatitis) and drug 
checking. Young Wave also provides psychedelic peer support (PsyHelp), 
an approach that aims to transform challenging psychedelic experiences 
into learning opportunities, and to reduce hospitalizations and other 
harms. The group also engages in policy advocacy, and it provides harm 
reduction training to police (88).
and C (49, 50). Direct‐acting 
antivirals are recommended for the 
treatment of all people with chronic 
hepatitis C infection (51). They have 
cure rates of around 95% and are far 
less toxic and better tolerated than 
interferon-based treatments (which 
are no longer recommended); they 
also can be provided to all persons 
with chronic hepatitis C infection. 
Several new direct-acting antiviral 
medicines have been approved by 
at one least stringent regulatory 
authority since 2013 (52).
Prevention strategies for hepatitis 
B infection among people who 
use drugs focus on vaccination 
and ensuring that sterile injection 
equipment is available. Hepatitis B 
infection is a chronic disease, and 
most people require ongoing antiviral 
treatment (53). 
Coverage
Direct-acting antiviral therapies are 
not yet widely accessible. In many 
countries, the high price of direct-
acting antiviral therapies or collateral 
fees charged for diagnosis makes 
access to them challenging for people 
who use drugs, and governments are 
reluctant to prioritize investment in 
the treatment (54, 55). Despite this, 
recent price reduction strategies, 
including the use of generics, 
have made direct-acting antivirals 
more affordable in a wide range of 
countries. 
In some countries, people who use 
drugs are often refused hepatitis C 
treatment, whether pre-emptively or 
through bureaucratic requirements 
(56). In some cases, individual 
providers and hospitals deny direct-
acting antiviral treatment to people 
who use drugs, in contravention 
of national policies (57, 58). This 
is despite evidence showing that 
treatment outcomes for people who 
inject drugs, including those actively 
using drugs, have been as good as 
with other patients (59).
Maximizing impact
Newly-published guidance on 
implementing comprehensive HIV 
and hepatitis C programmes for 
people who inject drugs recommends 
a set of practical approaches that 
are grounded in community 
empowerment (60). Wherever 
possible, health services for people 
who use drugs should be integrated. 
In countries with high tuberculosis 
incidence, harm reduction 
programmes should consider 
including the provision of 12-week 
tuberculosis prevention for people 
who use drugs when tuberculosis 
screening is negative. According 
to WHO, countries with low 
tuberculosis incidence may consider 
systematic testing for (and treatment 
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of) latent tuberculosis infection for all 
people who use drugs (61). 
Overdose management  
with naloxone
Evidence
Naloxone is an effective treatment for 
opioid drug overdoses. Improving 
access to naloxone through 
take-home programmes saves lives 
(62). Studies of community opioid 
overdose prevention show survival 
rates of 83–100% post-naloxone 
treatment (6). WHO guidelines 
recommend that all people likely 
to witness an overdose—including 
people who use drugs, their families 
and peers—should have access to 
naloxone (63). There are several ways 
to administer naloxone, including 
through intramuscular injection or 
nasal spray. 
Coverage
The availability of take-home 
naloxone is low. Among 108 countries 
that reported to UNAIDS in 2017, 
19 stated that they had naloxone 
available through community 
distribution. Civil society verified this 
in 53% of the reporting countries. 
Harm Reduction International’s most 
recent review of harm reduction data 
found that naloxone peer distribution 
was operational in 12 countries (see 
Annex 4 for details). However, not 
all countries that provide injectable 
naloxone also provide syringes 
within easy-to-use kits, and only 
five countries provide naloxone to 
prisoners upon release, despite the 
heightened risk of overdose that these 
individuals face (6). 
The cost of the medication is also an 
issue. In the States of America, prices 
for naloxone have risen by more than 
600% since 2015 (64). In Thailand, 
a project that facilitates access to 
naloxone in 19 Thai provinces is 
threatened due to diminishing 
national funds (6).
Several cities and countries have 
recently scaled up naloxone 
distribution alongside other harm 
reduction measures in response to 
rising overdose deaths (65–67). For 
example, the city of Dayton, Ohio, 
was once considered the epicentre of 
opioid-related fatalities in the United 
States. The establishment of a new 
compassionate approach to drug 
use in Dayton and the surrounding 
county—including the launch of 
harm reduction services that included 
needle–syringe and naloxone 
distribution—was followed by a 65% 
decline in overdose deaths in just one 
year, from 378 in the first half of 2017 
to 132 in the first half of 2018 (68).
Maximizing impact
Making naloxone available through 
peer distribution schemes and over 
the counter without a prescription 
improves uptake (6). However, legal 
and regulatory restrictions often 
block distribution to nonmedical 
personnel. Efforts to improve 
community distribution of intranasal 
sprays and kits with autoinjector 
intramuscular delivery systems 
include: (a) provision of education 
and training; (b) reduction of 
prescribing barriers to access; and (c) 
reduction of legal recrimination fears 
as barriers to use (69). Estonia and 
Scotland are among the jurisdictions 
providing easy-to-use injectable 
naloxone kits (66, 70). 
Supervised drug  
consumption sites
Evidence
While there has been insufficient 
research to date, evidence suggests 
that supervised drug consumption 
sites, also known as “drug 
consumption rooms,” reduce the risk 
of disease transmission and other 
harms, and that individuals who 
“LIKE FEMINISM, HARM REDUCTION IS A PHILOSOPHY 
THAT ENCOURAGES US TO DO AWAY WITH THE FALSE 
DISTINCTION BETWEEN ‘GOOD’ AND ‘BAD’ WOMEN.”
Fenya Fischler, Association for Women’s Rights in Development (AWID) (80)
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visit supervised drug consumption 
sites adopt safer injection practices 
when outside of the facilities (71). 
The International Narcotics Control 
Board (INCB) has noted that current 
research demonstrates that safe 
injecting facilities succeeded in 
attracting hard-to-reach populations, 
promoting safer injections and 
reducing overdose risk, and it has 
called for further research (72). 
Coverage
Supervised drug consumption sites 
now operate in at least 11 countries 
around the world: Australia, Belgium, 
Canada, Denmark, France, Germany, 
Luxembourg, Netherlands, Norway, 
Spain and Switzerland. Three 
countries are expected to open 
supervised drug consumption sites 
in 2019, namely Ireland, Mexico and 
Portugal (6). 
Needs of specific groups
There is a growing need for harm 
reduction services designed to 
meet the specific needs of various 
subpopulations of people who use 
drugs, including women, young 
people, people of diverse sexual 
orientations and gender identities, 
sex workers, people who use new 
psychoactive substances and people 
who need mental health care. 
Women
Women who use drugs face 
particular challenges in accessing 
harm reduction services (73). Higher 
levels of stigma and discrimination 
and harmful gender norms translate 
to lower control over injecting and 
more frequently being “second on 
the needle” during the sharing of 
injecting equipment (74). However, 
few harm reduction programmes 
tailor their services to meet the needs 
of women; sex and gender-based 
discrimination may make them 
unwelcoming (75, 76). Many such 
programmes do not provide childcare 
facilities, sexual and reproductive 
health services, services to tackle 
gender-based violence, adequate 
opening hours or staff trained to 
respond to gender-specific needs  
(76, 77). 
UNODC recommends gender-
responsive interventions that 
incorporate the needs of women into 
their design and implementation, 
including consideration of their 
location, staffing, programme 
development, approach and content 
(78). Addressing the sexual and 
reproductive health needs of women 
who use drugs is a critical aspect 
of comprehensive and integrated 
A community health worker picks up a five-day supply of methadone for clients, who can then access their daily dose at Rumah Singgah PEKA, a 
community-based harm reduction programme in Indonesia. PEKA, which aims to empower people who use drugs to re-establish control of their lives, 
has more flexible hours than public health facilities. Credit: UNAIDS/UNODC/Edward Wray.
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care. In 2018, WHO and UNFPA 
led a renewed call to action to 
strengthen delivery of linked sexual 
and reproductive health rights and 
HIV programmes and services as an 
essential focus for ensuring universal 
coverage (79). 
Young people
Young people who use drugs 
require special outreach by trusted 
intermediaries. Young people 
who inject drugs are particularly 
vulnerable to HIV infection and 
other blood-borne viruses, violence 
and human rights abuses. Guidance 
is available for working with this key 
population (81). 
One emerging approach is to reach 
young people at music festivals. 
In 2018, Australia’s New South 
Wales Ministry of Health published 
“IT HAS BEEN A CHALLENGE TO ADVOCATE 
FOR THE IMPLEMENTATION OF HARM 
REDUCTION-ORIENTED INTERVENTIONS 
IN LATIN AMERICA AND THE CARIBBEAN, 
DESPITE REPEATED EVIDENCE SHOWING 
ELEVATED HIV PREVALENCE RATES AMONG 
CERTAIN SUBGROUPS OF STIMULANT 
USERS, INCLUDING PEOPLE WHO USE 
STIMULANTS AND SELL SEX OR [THOSE 
WHO] ENGAGE IN STIMULANT USE AND 
CONCURRENT UNPROTECTED INSERTIVE 
ANAL OR VAGINAL SEX.”
Marcus Day, Caribbean Drug and Alcohol Research Institute (88)
The Narcotics Prison Cipinang in East Jakarta, Indonesia, is one of 11 model prisons implementing a comprehensive HIV programme where antiretroviral 
treatment and methadone services are provided. Credit: UNAIDS.
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CASE STUDY:  
REACHING WOMEN WHO 
INJECT DRUGS IN THE ISLAMIC 
REPUBLIC OF IRAN 
Iran is home to 200 000 people who inject drugs, 9.3% of whom are 
living with HIV. Women who use drugs are extremely marginalized and 
stigmatized, rejected by their families, and likely to live in extreme 
poverty without social support. 
Iran is one of the two countries in the Middle East and North Africa 
region to have adopted a national strategy that supports harm reduction 
and provides needle–syringe programmes and opioid substitution 
therapy (6). In 2016, 207 drop-in centres, 331 outreach teams and 68 
shelters provided harm reduction services to more than 125 000 people 
who use drugs (95). 
 
Iran offers several women-only drop-in harm reduction centres. The 
Rebirth Charity Organization began offering services to women who use 
drugs in 2002. A special residential facility houses pregnant women, and 
it was recently expanded to admit women with children under the age 
of six years. Women receive reproductive health services, HIV testing 
and linkages to treatment, drug treatment (including opioid substitution 
therapy), information about self-care and nutrition, training in parenting 
skills and more. The centre also houses a kindergarten. 
The facility is funded by the state, with individual benefactors providing 
in-kind contributions of food and clothing (95).
traditional psychoactive drugs 
have created a growing demand for 
synthetic substances that are not 
controlled by existing international 
conventions (77). People who 
inject these substances also face 
the additional risk of blood-borne 
infections (85). To address these 
risks, European harm reduction 
programmes have introduced drug 
checking, also known as “pill testing” 
or “reagent testing,” at clubs and 
festivals (86). 
Lesbian, gay, bisexual, transgender 
and intersex people and sex workers
When it comes to harm reduction 
services, the specific needs of 
lesbian, gay, bisexual, transgender 
and intersex (LGBTI) people and 
sex workers who use drugs are 
often overlooked in policies and 
programmes. Harm reduction 
programmes should take into account 
the individual, social and societal 
effects of drug use—and the specific 
risks and vulnerabilities faced by 
LGBTI people—in order to tailor 
evidence-informed interventions to 
their specific needs (89).
The International Network of People 
Who Use Drugs (INPUD) and the 
Global Network of Sex Work Projects 
(NSWP) note that harm reduction 
services are especially effective when 
education, empowerment, outreach 
and distribution are peer-led (90). 
A community-led harm reduction 
approach to chemsex in Australia 
led to increased service uptake (91). 
PrEP on demand may be a suitable 
approach for people who use drugs 
and practice chemsex when it is 
provided as part of a comprehensive 
prevention and harm reduction 
programme that is grounded in 
strong community engagement (92). 
Mental health care 
The multifaceted stigma and 
discrimination faced by people who 
use drugs has been linked to anxiety, 
depression, poor self-esteem and 
poor adherence to antiretroviral 
therapy. Mental health care (such as 
counselling) and psychosocial support 
programmes (such as support groups) 
can reduce self-stigma associated 
with HIV status, substance use and/or 
guidelines on harm reduction 
at festivals. Their recommended 
interventions include testing 
for STIs, provision of water and 
shade (to prevent dehydration 
and overheating), and the early 
involvement of peer-based harm 
reduction programmes in event 
planning (82). 
Users of new psychoactive 
substances
Hundreds of forms of new 
psychoactive substances are now 
circulating within global drug 
markets (83, 84). Drug control 
operations that aim to eliminate 
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mental health conditions; it also can 
promote adherence to treatment (93). 
More broadly, countries should act to 
remove the broader social stigma  
and discrimination that surrounds  
drug use.
Low investment
Overall financial investment in harm 
reduction services remains low. In 
2018, Harm Reduction International 
declared a “crisis” in harm reduction 
funding in low- and middle-income 
countries, stating that only 13% of 
the funding required annually for 
an effective HIV response for people 
who inject drugs was available (6). 
A comparison of UNAIDS Fast-
Track resource needs estimates and 
expenditure data that were reported 
by 17 low- and middle-income 
countries in 2017 and 2018 shows 
that spending on HIV programmes 
that focused on people who inject 
drugs was insufficient in all but 
three countries: Kenya, Nigeria and 
South Africa (96, 97). In many cases, 
expenditures were less than half of 
the resources needed for that year 
(Figure 13). 
Domestic funding appears to 
be particularly low. Among the 
31 countries that have reported 
expenditure data to UNAIDS since 
2014, 71% of the spending was 
covered by international donors.5
Donor expenditure data collected 
by UNAIDS show US$ 31.3 million 
(January to December 2016) and 
US$ 12.5 million (October 2016 to 
September 2017) in spending on 
HIV programmes focused on people 
who inject drugs in low- and middle-
income countries by the Global Fund 
to Fight AIDS, Tuberculosis and 
Malaria (Global Fund) and the United 
States President’s Emergency Plan for 
AIDS Relief (PEPFAR), respectively. 
According to Harm Reduction 
International, support for harm 
reduction in low- and middle-income 
countries from the Global Fund was 
18% lower in 2016 than in 2011 (6).
“FUNDING FOR HARM REDUCTION IS IN CRISIS GLOBALLY, ESPECIALLY 
FOR SERVICES DESIGNED TO MEET THE NEEDS OF PEOPLE WHO DON’T 
INJECT DRUGS. IF THE UN WERE TO DEVELOP ROBUST TECHNICAL 
GUIDANCE ON HARM REDUCTION FOR NON-INJECTING POPULATIONS, 
IT WOULD HELP STRENGTHEN THE CALL ON DOMESTIC GOVERNMENTS 
AND DONORS TO INVEST IN HOLISTIC HEALTH AND SOCIAL SERVICES 
FOR PEOPLE WHO USE DRUGS.”
Olga Szubert, Harm Reduction International (94)
5. Afghanistan, Algeria, Armenia, Azerbaijan, Bangladesh, Belarus, Benin, Dominican Republic, Kazakhstan, Kenya, Kyrgyzstan, Lao People’s Democratic Republic, 
Latvia, Madagascar, Malawi, Malaysia, Mexico, Mozambique, Myanmar, Namibia, Nepal, Nigeria, Republic of Moldova, Romania, Russian Federation, Samoa, Senegal, 
Seychelles, South Africa, Tajikistan and Ukraine.
These figures only include 
expenditures on service provision. 
They do not include expenditures 
for social enablers, such as advocacy 
and work on law reform, training 
and sensitization of law enforcement 
personnel, programmes to reduce 
stigma and discrimination, violence 
prevention, legal empowerment and 
rights education of communities, 
programmes to reduce harmful 
gender norms, and empowerment 
of community and peer support 
networks. Investment in social 
enablers is essential to fulfilling the 
rights of people who use drugs. 
In the 2016 Political Declaration on 
Ending AIDS, countries committed 
to ensuring that at least 6% of HIV 
resources are allocated for social 
enablers. Despite this, political and 
administrative barriers to financing 
social enablers persist, impeding 
access to funding for civil society 
groups. 
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Figure 13. Expenditures on HIV programmes focused on people who inject drugs, 
17 countries, 2016–2017, and resource needs for the reporting year and 2020
  Expenditures        Resource needs
Sources: UNAIDS HIV Financial dashboard; UNAIDS Global AIDS Response Progress Reporting and Global AIDS Monitoring reports 2015–2018; Stover J, 
Bollinger L, Izazola JA, Loures L, DeLay P, Ghys PD et al. What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact 
of the Fast-Track Approach. PLoS ONE. 2016;11(5):e0154893. 
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“BELARUS IS EXPANDING ITS FUNDING BOTH FOR HIV TREATMENT 
AND FOR HIV PREVENTION AMONG PEOPLE WHO INJECT DRUGS. 
BELARUS IS ONE OF REGIONAL LEADERS IN USING SOCIAL 
CONTRACT MECHANISMS TO SUPPORT HARM REDUCTION SERVICE 
PROVISION THROUGH NONGOVERNMENTAL ORGANIZATIONS.”
Dmitry Pinevich, First Deputy Minister of Health, Belarus (98)
Universal health coverage and 
the problem of discrimination
As part of the Sustainable 
Development Goals, all countries 
have committed to achieving 
universal health coverage as a core 
driver of development (99). However, 
expanding health coverage alone 
has not been an effective solution to 
the problem of expanding access to 
health services for people who inject 
drugs. Harm reduction services and 
treatment of drug dependence may 
be excluded from health insurance 
coverage, and numerous quantitative 
and qualitative studies have found 
that people who use drugs experience 
stigma and discrimination in the 
health sector, which deters them from 
seeking health services (59, 100–103). 
The global campaign for primary 
health care and universal health 
coverage should give special attention 
to the needs of people who use drugs, 
as their extreme marginalization 
makes their experiences a litmus 
test for the success of these broader 
efforts. To find practical solutions to 
these challenges during the roll-out 
of universal health coverage schemes, 
states should ensure that civil society 
groups led by people who inject 
drugs participate meaningfully in 
health governance. This includes 
participating in resource allocation 
decisions and at all stages of policy-
making, implementation and 
evaluation. States should also take 
steps to address the persistent human 
rights barriers to health services 
that are faced by people who use 
drugs by investing in community-led 
advocacy and service provision and 
access to justice. service provision, 
and by establishing systems for 
social contracting. These issues are 
discussed further in the next two 
sections.
31
Sino, an outreach worker from Trust Point Centre, Khorog, Tajikistan, distributes sterile injecting equipment and information leaflets in Khorog bazaar. 
Credit: Global Fund/John Rae. 
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The stated purpose of international 
drug policy is to safeguard the 
health, well-being and security of 
people and society. The dominant 
approach to illicit drugs, however, 
continues to be one of criminalization 
and incarceration. This is despite 
countries agreeing again and again, 
including within the Commission 
on Narcotic Drugs and at the 2016 
United Nations (UN) General 
Assembly Special Session, , that drug 
policy must be informed by human 
rights and committing to adopt a 
more balanced, integrated, evidence-
informed and human rights-based 
approach (1–3).
Criminalization
Criminalization of activities related to 
personal drug use has been shown to 
increase stigma and discrimination, 
decrease the availability and 
accessibility of HIV and harm 
reduction services, and drive people 
who use drugs away from the services 
that are available (4, 5).  
Such criminalization also has been 
linked to police abuse, including 
coerced confessions, torture and 
extortion of bribes (6, 7). It has 
disastrous effects on the families of 
those detained, such as removing 
children from the care of their parents 
(5, 7, 8). 
Decriminalization entails countries 
removing criminal penalties on 
the use, possession and sometimes 
cultivation of small quantities of drugs 
for personal use. In some models of 
decriminalization, these activities 
remain subject to fines or other 
administrative penalties. In other 
frameworks, the state removes all 
penalties for use or possession within 
authorized parameters. Legalization 
entails the legal cultivation and sale of 
controlled substances, within certain 
parameters. In Portugal, for example, 
decriminalization of activities related 
to drug use—along with the scale-up 
of harm reduction and related 
services—triggered a sharp decline in 
the incidence of HIV infection related 
to injecting drug use and a decline in 
the numbers of those incarcerated (9).
A growing number of public health 
and professional bodies have called 
for decriminalization (11). UN human 
rights treaty bodies, human rights 
special procedures, UN agencies, 
regional human rights bodies, and 
the Global Commission on HIV 
and the Law have additionally found 
that criminalization of drug use and 
“AS COMMUNITIES OF PEOPLE WHO USE 
DRUGS, WE BELIEVE THAT THE ONLY WAY FOR 
RIGHTS AND DIGNITY TO BE RESTORED IS FOR 
DRUG USE AND PEOPLE WHO USE DRUGS TO 
BE DECRIMINALIZED.”
Judy Chang, International Network of People Who Use Drugs (INPUD) (26)
OVERCOMING
THE HUMAN
RIGHTS
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The Myanmar Anti-Narcotics Association (MANA) works to reduce HIV among people who inject drugs by raising awareness of behavioural risks and 
by supplying sterile injecting equipment. MANA also provides basic medical care, testing and counselling, and support for people who inject drugs to 
transition to opioid substitution therapy. Credit: Global Fund/John Rae.
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possession for personal use amounts 
to a breach of human rights and have 
called for their decriminalization 
(12–17). 
For decriminalization of activities 
related to personal drug use to work 
well in practice, the alternatives to 
incarceration must be appropriate, 
proportionate and voluntary. 
Compulsory detention and treatment 
is not an acceptable alternative. High 
fines can place a heavy financial 
burden on people who use drugs 
and their families, sometimes also 
resulting in imprisonment (18, 19). 
In 2018, the International Drug 
Policy Consortium reported 
that 26 countries now take a 
decriminalization approach to 
activities related to personal drug 
use (20). A few countries, such as 
Canada and Uruguay, have legalized 
the personal possession of cannabis 
entirely (21).
Despite the growing global consensus 
on decriminalization of activities 
related to personal drug use, most 
countries continue to criminalize 
activities related to personal drug use 
or to impose coercive and punitive 
responses. Some countries have 
increased penalties and intensified 
policing efforts in recent years. In 
January 2017, for example, Lithuania 
criminalized the possession of 
any amount of drugs, resulting in 
hundreds of arrests for possession 
of small amounts (18). In the 
Philippines, a national campaign to 
crack down on the drug trade has 
resulted in thousands of extrajudicial 
killings (22, 23). According to 
Amnesty International, one result of 
the campaign has been that people 
who inject drugs in the Philippines 
are now afraid to seek out HIV 
testing and treatment (24). In 2018, 
38 members of the UN Human Rights 
Council issued a statement urging 
the Philippines to end extrajudicial 
killings and to allow an independent 
investigation (25). 
Disproportionate sentencing, 
including the death penalty
The UN Human Rights Committee 
has called on countries that have 
the death penalty to restrict its use 
to the most serious crimes and only 
in exceptional circumstances. To do 
otherwise breaches the right to life 
under the International Covenant 
on Civil and Political Rights. Such 
exceptional circumstances, according 
to the Committee, do not include 
drug crimes (27). The International 
Narcotics Control Board (INCB) also 
has encouraged states to abolish the 
death penalty for drug crimes (28). 
In 2018, 35 countries or territories 
retained the death penalty for drug 
offenses. Since 2015, there has been a 
steady decline in known executions of 
persons who have been convicted of 
a drug offence (29). Harm Reduction 
International documented fewer 
than 100 such executions in 2018, the 
lowest since it started collecting data 
in 2008 (29).6 More than 7000 people 
were on death row for drug offences 
globally in 2018 (29).
Some countries have begun to relax 
drug-related sentencing. Malaysia, 
for example, has signalled that it will 
remove the death penalty for drug-
related offences (30). Prior to 2017, 
the Islamic Republic of Iran had one 
of the highest rates of executions for 
drug-related offences, but it revised 
the legal threshold for drug-related 
death sentences in 2017, leading to 
“BASICALLY THE POLICE SEEM TO BE A MAIN BARRIER 
FOR HARM REDUCTION POLICY IMPLEMENTATION.HOWEVER, 
IF THE POLICE WORK CLOSELY WITH CIVIL SOCIETY, IT WILL 
HELP A LOT IN TERMS OF HIV PREVENTION AND HARM 
REDUCTION SERVICE PROVISION.”
Krisanaphong Poothakool, Police Lieutenant Colonel, Royal Police Cadet Academy, Thailand (36)
6. Four countries—China, the Islamic Republic of Iran, Saudi Arabia and Singapore—were known to have executed people for drug offences in 2018.
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a sharp decrease in the number of 
drug-related executions (from 221 in 
2017 to 23 cases in 2018) (29).
Law enforcement and access 
to harm reduction
UN human rights mechanisms, 
including the Human Rights Council, 
have affirmed that access to harm 
reduction services is a human 
right (31).7 Despite overwhelming 
evidence of the effectiveness of 
harm reduction services, laws and 
practices in a number of countries 
restrict these services (32). Even 
where harm reduction services are 
not legally restricted, some actions by 
law enforcement agents can impede 
access to them. 
Confiscating injecting equipment, 
even in places where needle–syringes 
are not legally restricted, discourages 
individuals from carrying and using 
them. People who have experienced 
random drug testing are more 
likely to avoid health care, and 
arresting people who inject drugs 
when they visit harm reduction 
sites has the predictable effect of 
discouraging use of such services 
(6). Requiring individuals to register 
for harm reduction services, either 
with health services or with the 
police, also discourages their use. 
Violations of patient confidentiality 
have been frequently documented 
in countries that maintain such 
registries, with police obtaining 
identifying information and using it 
to target individuals (33). Arresting 
people who inject drugs when they 
contact emergency services for 
assistance with an overdose is another 
discouraging practice (34).
In some countries, law enforcement 
personnel are actively calling for 
change. For example, the Center for 
Law Enforcement and Public Health 
and the Law Enforcement Action 
Partnership have prepared a police 
statement of support for drug policy 
reform that calls for decriminalization 
and harm reduction (35).
Compulsory treatment
Twelve UN agencies, the INCB 
and numerous UN human rights 
mechanisms and bodies have called 
for the closure of compulsory drug 
detention and treatment centres  
(38–40).8 The Global Fund to Fight 
AIDS, Tuberculosis and Malaria 
(Global Fund) has committed to 
not funding compulsory treatment 
programmes or facilities, and both 
the UN Working Group on Arbitrary 
“WHATEVER THEIR OWN PERSONAL BELIEFS, POLICE SHOULD NOT 
PUT THEIR MORAL JUDGEMENT OVER PUBLIC HEALTH; PEOPLE 
WHO USE DRUGS ARE HUMAN BEINGS WITH HEALTH PROBLEMS, 
AND THE PROPER APPROACH FOR POLICE IS HARM REDUCTION.”
Assistant Commissioner of Police, Jones Blantari, Ghana Police (37)
Detention and the Committee on the 
Elimination of Discrimination against 
Women (CEDAW) have expressed 
concern at the continuing practice 
in some countries of incarcerating 
pregnant women who use drugs, 
either for involuntary treatment or 
punitive detention (40–42).
However, at least 11 countries in 
South-East Asia and a number of 
countries in Latin America and the 
Caribbean continue to detain people 
who use drugs in compulsory drug 
detention centres (18). These facilities 
have been linked to torture, forced 
labour and other abuses (43). In 
South-East Asia, an estimated  
450 000 people were detained in 948 
compulsory drug detention centres in 
2017 alone (44). According to Harm 
Reduction International, the practice 
is escalating in some countries (18). 
Other countries provide little or no 
state supervision to similarly abusive 
centres in the private sector (20). 
Stigma and discrimination and 
privacy
Stigma and discrimination in health-
care settings undermines access to 
services for people who use drugs 
(45, 46). Stigma is reinforced by 
criminal laws, policing and other 
7. For example, see: The Committee on Economic, Social and Cultural Rights. Concluding observations on the combined fifth and sixth periodic reports of the Philippines. 
UN Doc. E/C.12/PHL/CO/5-6. 26 October 2016; CESCR. Concluding observations on the combined second to fourth periodic reports of the former Yugoslav Republic 
of Macedonia, UN Doc. E/C.12/MKD/CO/2-4 (2016); CEDAW. Concluding observations on the combined fourth and fifth periodic reports of Georgia, UN Doc. 
CEDAW/C/GEO/CO/4-5; and CRC. General comment 21 on children in street situations, UN Doc. CR/GC/21 (2017).
8. For a compilation of statements from 2008 to 2014, see: Amon J, Pearshouse R, Cohen J, Schleifer R. Compulsory drug detention in East and Southeast Asia: evolving 
government, UN and donor responses. Int J Drug Policy. 2014:25;13–20.
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structural barriers that perpetuate 
violence, exploitation and a climate 
of fear. This undermines efforts to 
provide condoms and harm reduction 
services and to prevent the spread of 
HIV (4, 6). 
Some subpopulations of people who 
use drugs face multiple intersecting 
forms of stigma that render them 
more vulnerable to discrimination, 
violence and exploitation. For 
example, sex workers who use drugs 
may experience drug-related stigma 
from other sex workers and sex work-
related stigma from people who use 
drugs. They also face greater risk of 
arrest or abuse by law enforcement 
(47). 
In 2016, UN Member States 
committed to ending HIV-related 
stigma and discrimination, including 
stigma and discrimination towards 
people who use drugs and other key 
populations (48). 
At its 2016 Special Session on the 
World Drug Problem, the UN 
General Assembly encouraged states 
to “prevent social marginalization 
and promote non-stigmatizing 
attitudes, as well as to encourage drug 
users to seek treatment and care, and 
take measures to facilitate access to 
treatment and expand capacity” (3). 
In 2017, 12 UN agencies issued 
a Joint UN Statement on Ending 
Discrimination in Health Care 
Settings, recognizing discrimination 
CASE STUDY:  
CALLING FOR CHANGE 
IN WEST AFRICA 
West Africa has long been affected by drug trafficking, with drug use 
recently on the rise. Countries in the region have been slow to react 
to this trend. In West Africa, only Senegal offers both needle–syringe 
programmes and opioid substitution therapy (18).
In 2018, the West Africa Commission on Drugs took action, producing 
the Model Drug Law for West Africa. The Model Law builds upon 
international commitments at the 2016 United Nations Special Session 
on the World Drug Problem and on the Economic Community of West 
African States Action Plan to Address Illicit Drug Trafficking, Related 
Organized Crime and Drug Abuse in West Africa (2016–2020). The 
Model Law calls for the removal of criminal penalties for drug use 
or possession of drugs for personal use, and for strong protections 
against law enforcement abuses. It also recommends delivery of harm 
reduction services, including evidence-informed drug treatment, and 
calls on countries to ensure that the possession of syringes cannot be 
considered evidence of a crime (56).
Olusegun Obasanjo, former President of Nigeria and Chair of the 
West Africa Commission on Drugs, says that while existing laws tend 
to criminalize drug users, evidence shows that jailing growing numbers 
of people who inject drugs is no solution: “On the contrary, it worsens 
health issues, and puts enormous pressure on the already overstretched 
criminal justice system” (57).
The West Africa Commission on Drugs is an independent high-level 
drug policy group. Development of the Model Drug Law was supported 
by the Kofi Annan Foundation, the Global Commission on Drug Policy 
and the Open Society Initiative for West Africa. Regional drug policy 
reform is also championed by the West Africa Drug Policy Network, 
which unites more than 600 civil society organizations in 16 countries. 
“The Model Drug Law is relevant globally. A good drug law in West 
Africa needn’t look any different from one in Asia or eastern Europe,” 
says Jamie Bridge of the International Drug Policy Consortium. “It was 
designed and developed for the region; it was based on an assessment 
of drug laws in the region; it was led by regional experts and opinion 
leaders. But it is not just a West African resource” (58).
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as “a major barrier to the achievement 
of the Sustainable Development 
Goals” (15). In March 2018, the 
CND passed a resolution calling 
on countries to develop policies to 
improve the accessibility, availability 
and delivery of health care and 
social services for people who use 
drugs. The resolution also states that 
governments should work to reduce 
stigmatizing attitudes within agencies 
and any possible discrimination, 
exclusion or prejudice those people 
might encounter (2). 
In November 2018, the United 
Nations Development Program 
(UNDP), United Nations Entity 
for Gender Equality and the 
Empowerment of Women (UN 
Women), UNAIDS and the Global 
Network of People Living with HIV 
launched the Global Partnership 
for Action to Eliminate All 
Forms of HIV-related Stigma and 
Discrimination, including against 
people who use drugs. The goal 
of the partnership is to encourage 
commitments and actions to remove 
the barriers to health care and other 
services created by stigma and 
discrimination (49). 
UNAIDS has previously identified 
seven key programmes to remove 
stigma and discrimination and 
increase access to justice that can be 
adapted to the context of people who 
use drugs:
1. Stigma and discrimination 
reduction. 
2. Accessible and appropriate legal 
services. 
3. Monitoring and reforming laws, 
regulations and policies relating to 
people who use drugs. 
4. Legal literacy (“know your rights”). 
5. Sensitization of law-makers and 
law enforcement agents. 
6. Training for health-care providers 
on human rights and medical 
ethics related to people who use 
drugs. 
7. Reducing discrimination against 
women in the context of drugs (50).
Support and guidance for a 
human rights-based approach 
to drug policy
Since 2016, a growing chorus of 
UN agencies and international and 
regional human rights mechanisms 
has called for a human rights-
based approach to drug policy (14, 
51). In 2018, the UN Common 
Position on International Drug 
Policy reiterated the United Nations’ 
A volunteer from Prison Number 18 in Bra˘nes¸ti, Republic of Moldova, helps run the needle–syringe exchange programme by exchanging non-sterile 
injecting equipment for sterile equipment. Along with sterile injecting equipment, inmates also have access to disinfectants, condoms and informational 
materials on HIV, hepatitis, tuberculosis and other infectious diseases. Credit: UNAIDS.
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CASE STUDY:  
LAW ENFORCEMENT 
FOR A CHANGE 
Law Enforcement Assisted Diversion (LEAD) is a project in the city of 
Seattle in the United States of America that provides an alternative to 
criminal penalties for the possession of under three grams of drugs for 
personal use. Instead of charging individuals with criminal possession, 
police officers establish a contact for the person with a case manager.  
Case managers help LEAD clients, many of whom are homeless or 
unemployed, receive support services such as housing, job placement  
and drug treatment (66). 
Harm reduction is a core principle of LEAD. Recognition of the critical 
importance of social determinants of health and providing social 
protection services to people who inject drugs has helped LEAD achieve 
impressive outcomes. Research shows that LEAD participants were 60% 
less likely to be arrested during the six months subsequent to evaluation 
entry, and that they were both 58% less likely to be arrested and 39% 
less likely to be charged with a felony over the longer term compared to 
persons not in the programme (67). Moreover, among LEAD participants, 
access to housing and employment were associated with 17% and 33% 
fewer arrests during the follow-up, respectively (68).
LEAD has built collaborations with police, prosecutors, civil rights 
advocates, public defenders, political leaders, mental health and drug 
treatment providers, and housing agencies. After a pilot phase, which 
included a randomized controlled trial, LEAD has scaled up across the 
United States, with programs in 32 cities and 19 states. 
“strong commitment to supporting 
Member States in developing and 
implementing truly balanced, 
comprehensive, integrated, 
evidence-based, human rights-
based, development-oriented and 
sustainable responses to the world 
drug problem, within the framework 
of the 2030 Agenda for Sustainable 
Development” (52).
With this increasing level of agreement 
on how to approach the issue has 
come a need for guidance on how to 
implement it (53). Examples of best 
practices, model laws and policies are 
now available:
 The WHO Consolidated guidelines 
on HIV prevention, diagnosis, 
treatment and care for key 
populations, which was updated in 
2016 (54).
 The forthcoming International 
guidelines on human rights and 
drug policy, which articulates that 
drug policy should be informed 
by a number of rights, such as the 
rights to health, life, privacy, an 
adequate standard of living, fair 
trial, freedom from torture and 
participation in cultural life (53). 
 The European Commission 
recommendations on alternatives 
to coercive sanctions for drug-
related crime (55). 
 The West African Commission 
on Drugs Model Drug Law for 
West Africa, which calls for the 
protection of various human 
rights and provides an example 
of decriminalization of the 
possession, cultivation, transport 
and purchase of drugs for personal 
use (see text box on page 37). (56). 
A selection of UN and regional 
publications and resolutions that 
articulate a human rights-based 
approach to drug policy can be found 
in Annex 5.
Social protection
People who use drugs may have 
complex health and social needs. 
They are more likely to be homeless, 
unemployed, living in poverty, 
facing mental health difficulties 
and experiencing multiple forms of 
violence (20, 59, 60). They are often 
excluded from social protection 
services that could help them 
overcome these challenges, including 
housing, educational grants and 
welfare payments. Some countries 
have been known to make welfare 
benefits conditional on drug testing, 
a practice that UN human rights 
mechanisms have condemned (61, 62).
Subsidized housing for homeless 
people, access to food and nutrition 
programmes, and free access to 
transportation are all important 
measures that can increase the use 
of (and retention in) HIV care for 
people who use drugs (68). In Hong 
Kong, the Support Fund for  
HIV/AIDS Patients and Their Families 
provides temporary financial 
assistance to cover basic needs, 
special medical expenses and travel 
expenses to receive care and other 
needs (64). In Portugal, reintegration 
teams help individuals recovering 
from drug dependence find 
employment and housing (65).
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In the global effort to promote rights- 
and health-based approaches to 
drug use, especially in places where 
repressive policies and practices are 
the norm, civil society is an essential 
source of information, mobilization, 
advocacy and life-saving services. 
Community-led mobilization has 
helped to shape and drive policy 
progress in many parts of the world. 
Since 2013, the international Support 
Don’t Punish campaign has mobilized 
thousands of people in more than 100 
cities to take part in a global day of 
action for health- and rights-based 
drug policies. From a bicycle rally of 
activists and law enforcement agents 
in Pokhara, Nepal, to a giant mural 
in the centre of Melbourne, Australia, 
and high-level policy dialogues in 
Paris and Phnom Penh, the Support 
Don’t Punish campaign has mobilized 
and convened advocates around the 
world (1). Mothers of people who use 
drugs have also emerged as a force for 
reform: in 2018, the Listen to Mom 
campaign brought together mothers’ 
groups from Canada, Mexico and the 
United States of America to advocate 
for the end of criminalization and for 
harm reduction services (2). 
 
At the national level, advocates 
have supported capacity-building 
and dialogue with government 
officials. Civil society advocates 
participated in national drug policy 
dialogues in Ukraine, provided 
training for members of the National 
Commission to Combat Drugs 
in the Republic of Moldova, and 
organized a successful visit by 
Moldovan government officials 
to Portugal (3, 4). In the Russian 
Federation, civil society has played 
an active role in creating a body of 
treaty recommendations directed 
at the government in relation to 
both drug policy and the increasing 
restrictions that have been placed on 
civil society (5).
At the regional level, civil society 
advocacy has played a critical role 
in changing attitudes and discourse 
on drug policy and approaches to 
protecting and improving the health 
of people who use drugs. In the 
Middle East and North Africa, the 
Middle East and North Africa Harm 
Reduction Association promotes 
harm reduction to government 
officials and religious leaders (7). 
“WE CANNOT ISOLATE DRUG POLICY FROM 
THE GLOBAL POLITICAL CONTEXT, IN WHICH 
THE RHETORIC OF CONTROL, REPRESSION 
AND EXCLUSION HAS BECOME DOMINANT 
IN RECENT YEARS. POLITICAL POPULISM 
HAS NEGATIVE CONSEQUENCES FOR HARM 
REDUCTION AND DRUG POLICY.”
Peter Sarosi, European Union Civil Society Forum on Drugs (23)
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Civil society in eastern Europe and 
central Asia has advanced hepatitis 
C treatment by pushing for the 
registration of and access to new 
direct-acting antiviral treatment (8). 
As part of a European Union-
funded project in three Baltic states, 
civil society worked together with 
governmental agencies to develop a 
methodology for drug policy impact 
assessment, using these results to 
inform the development of a national 
drug policy strategy (9).
Globally, harm reduction policies 
have progressed, in part thanks 
to persistent advocacy and the 
development of new, broader 
coalitions. Civil society organizations 
led by people who use drugs, 
harm reduction advocates, 
human rights advocates and allied 
nongovernmental organizations have 
worked together to submit shadow 
reports to United Nations (UN) 
human rights treaty bodies, leading 
those mechanisms to submit stronger 
recommendations to countries 
(10–15). International human 
rights institutions and women’s 
organizations have also put out 
stronger positions and calls to action 
on drug policy reform (16–18). 
Civil society also plays a vital role in 
delivering harm reduction services to 
the people who need them. As new 
drugs emerge, new types of peer-led 
services also appearing. These can 
include sharing information on 
safer drug use techniques and the 
administration of naloxone. They 
can also include drug checking, 
providing vitamins and fluids, and 
offering many forms of psychological 
support. In Saint Petersburg, Russian 
Federation, nongovernmental 
organizations such as EVA work 
with smaller nonprofit organizations 
to provide peer outreach services 
A participant at a meeting of a self-support group for people who inject drugs convened by the association Le Foyer du Bonheur in Côte d'Ivoire. 
Credit: Global Fund/Georges Mérillon.
and monitor funding for HIV 
programmes serving key populations 
(19, 20).
The outcome document from 
the 2016 Special Session on the 
World Drug Problem reiterated 
the role of civil society and affected 
populations in the formulation, 
implementation and evaluation 
of drug policies and programmes. 
Financing this work continues to 
be a challenge in many countries. 
The 2016 Political Declaration on 
Ending AIDS committed to ensuring 
that 30% of the HIV response was 
community-led, and that 6% of all 
HIV financing was dedicated to 
social enablers, including advocacy 
and community mobilization 
(21). The Global Fund to Fight 
AIDS, Tuberculosis and Malaria 
(Global Fund) has similarly set 
key performance indicators for its 
current strategy, committing to 
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CASE STUDY:  
HIV PREVENTION 
AMONG PEOPLE WHO INJECT 
DRUGS IN THE RUSSIAN 
FEDERATION
The Russian Federation has one of the largest populations of people 
who inject drugs in the world, and also a growing HIV epidemic: from 
an estimated 95 000 new infections (among all ages) in 2015 to 100 000 
in 2017. In 2017, HIV prevalence among people who inject drugs in six 
cities was 75.2% (31). However, federal laws prohibit the provision of 
opioid substitution therapy, and nongovernmental organizations that 
receive international funding may be listed as foreign agents. 
Until 2018, HIV prevention needle–syringe programmes were provided 
in only 17 cities. However, in Saint Petersburg, the Russian Federation's 
second largest city, civil society organizations have succeeded in 
forging a partnership with local authorities and obtaining government 
funding (32–33).
 
Since 2001, the nongovernmental organization Humanitarian Action has 
offered a needle–syringe programme through a mobile unit, along with 
rapid HIV testing and counselling, referral to medical treatment for HIV 
and tuberculosis, and naloxone distribution. It has specific interventions 
for female sex workers who use drugs and for pregnant women who 
inject drugs. In 2018, Humanitarian Action provided HIV prevention 
services to more than 30 000 people, with approximately half of all 
clients being people who inject drugs (34).
 
In recent years, Saint Petersburg is one of the only cities and regions in 
the Russian Federation that has reported a consistent decrease in new 
HIV infections, including among people who inject drugs.
According to Sergey Dugin, the director of Humanitarian Action, “Saint 
Petersburg implements a test-and-treat approach for HIV.” For hepatitis 
C, he says, the picture is less rosy: “Only one or two of our clients got 
treatment” for hepatitis C coinfection in the previous year. “There is 
simply no budget for it” (34).
increasing funding for programmes 
that address human rights barriers to 
services, especially in middle-income 
countries (22).
However, limited financing and 
narrowing civic space in many 
countries creates numerous challenges 
to civil society engagement. As 
donors transition out of middle-
income countries, financing for civil 
society to engage in drug policy and 
provide harm reduction services is 
frequently at risk. In Bulgaria, for 
example, the funding allocated in 
the national HIV response for key 
populations is less than half of the 
amount previously provided by 
the Global Fund (24). As part of 
sustainability planning, donors and 
recipient countries should ensure 
continuity of funding before they 
begin transition processes. Many 
civil society organizations are 
focusing advocacy on this issue and 
collaborating with groups that are 
experienced in this area. The Eurasian 
Harm Reduction Association’s 
(EHRA) Budget advocacy guide is the 
result of one such partnership (25).
In social contracting, government 
agencies contract services to civil 
society service providers (27). 
Unfortunately, civil society 
organizations that represent or serve 
the needs of people who use drugs 
often face institutional barriers to 
registration and operation. In several 
countries, increasingly restrictive 
regulations have limited their work 
(28). In the Russian Federation, for 
example, civil society organizations 
have been required to register as 
foreign agents because they received 
funding from international donors 
(29, 30). It is critical that countries 
begin to develop social contracting 
systems and policies as they prepare 
to transition from donor support; this 
will help to ensure that life-saving 
services are not abruptly shuttered.
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“IN THE PROCESS OF TRANSITION FROM DONOR TO NATIONAL 
FUNDING, HARM REDUCTION AND OPIOID SUBSTITUTION THERAPY 
PROGRAMMES ARE THE FIRST AT THE RISK OF DISCONTINUATION.  
IN KAZAKHSTAN IN 2018, WE MANAGED TO PRESERVE THE NATIONAL 
OPIOID SUBSTITUTION THERAPY PROGRAMME LARGELY DUE TO 
THE FACT THAT CLIENTS INITIATED A CAMPAIGN AGAINST OPIOID 
SUBSTITUTION THERAPY CLOSURE . . . AND THE KAZAKHSTAN 
GOVERNMENT TOOK THESE ARGUMENTS INTO CONSIDERATION,  
SO THE CURTAILMENT ORDER WAS CANCELLED. BY THE BEGINNING 
OF 2019, THE ENROLMENT OF NEW CLIENTS FOR THE OPIOID 
SUBSTITUTION THERAPY PROGRAMME HAD STARTED.”
Oxana Ibragimova, Steering committee member, representative of Central Asia, Kazakhstan Network of People 
Living with HIV) (26)
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The overarching objective of the 
global drug control framework is 
the health, well-being and security 
of individuals. The interpretation of 
this objective into a criminalization 
and law enforcement approach 
has demonstrably failed to achieve 
global targets to “eliminate or reduce 
significantly and measurably” the 
supply and demand for illicit drugs 
by 2019. UNODC data show that 
the drug trade and drug use have 
not decreased in the 10 years since 
these targets were included in the 
2009 Political Declaration and Plan of 
Action on International Cooperation 
towards an Integrated and Balanced 
Strategy.
Worse, the punitive approach has 
caused untold harm to people who 
use drugs and their families, and 
it has resulted in wider human, 
economic and environmental costs. 
Rates of HIV, viral hepatitis and 
tuberculosis remain high among 
people who use drugs, and violence 
and overdose have taken countless 
lives.
Comprehensive harm reduction 
services—including needle–syringe 
programmes, drug dependence 
treatment, overdose prevention 
with naloxone, and testing and 
treatment for HIV, tuberculosis, 
and hepatitis B and C—is what is 
needed to secure the health and well-
being of people who use drugs. The 
decriminalization of drug use and 
possession for personal use has been 
shown to facilitate access to harm 
reduction services and improve rights 
protections for people who use drugs.
As a new chapter in the response 
to the world drug problem begins, 
UNAIDS calls on countries to adopt 
the recommendations contained 
within this report, and to rapidly 
transform those commitments into 
laws, policies, services and support 
that allow people who use drugs to 
live healthy and dignified lives.
CONCLUSION
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Number of needle–syringes distributed per person who injects drugs, per year, by needle–syringe 
programmes, 2011–2017
ANNEX 1
Country 2011 2012 2013 2014 2015 2016 2017
Afghanistan 80 119 92 80
Albania 90 6 7 7
Armenia 28 44 54 65 72 76
Australia 203 268 625
Azerbaijan 11 10 16 26 23 10 35
Bangladesh 264 237 287 224 243 157 125
Belarus 48 21 37 64 41 70
Bosnia and Herzegovina 26 51 24 100 88 142
Bulgaria 22 21 14 13 36 21
Cambodia 120 129 326 253 371 382 305
China 180 193 204 208
Czechia 202 200 204
Estonia 153 242 235 237 230
Finland 202 196 281 361
Georgia 22 23 45 79 80 91 73
Greece 7 56 53 69 52
Hungary 114 74 114 76
India 387 163 193 240 259 284 424
Indonesia 7 22 26 44 13 9 3
Iran (Islamic Republic of) 30 74 63 51 34 50
Kazakhstan 154 190 224 189 128 120 129
Kenya 15 72 155 189
Kyrgyzstan 151 253 292 252 241 153 224
Lao People's Democratic Republic 17 30 3
Latvia 19 33 49 62 93
Lithuania 32 58 52 65 102
Madagascar 0 0 0 0 0 0 8
Malaysia 1 43 31 26 14
Malta 302 212 475
Mauritius 31 50 46 107 123 91
Mexico 7 12 20 4 7 6 6
Morocco 44 75 68 80 99 54 69
Myanmar 118 116 147 168 223 313 358
Nepal 71 36 31 36 25 61
North Macedonia 23 28 33 62
Pakistan 42 98 131 194 194 51 49
Poland 78 47 34
Republic of Moldova 58 60 65 68 78 88 79
Romania 49 52 194 187 198 166
Serbia 4 5 16
Seychelles 0 6 9
Tajikistan 88 199 175 214 283 345 273
Thailand 10 12 12 14 6 13 13
Tunisia 15 9 5 15 27 17 41
Ukraine 75 77 66 63 71 84
United Republic of Tanzania 41 14 17 15
Uzbekistan 54 68 68 62 62 119
Viet Nam 140 180 98 62 148 149
  <100         100–200         >200
Source: UNAIDS Global AIDS Monitoring, 2011–2017.
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Source: UNAIDS Global AIDS Monitoring, 2011–2017.
Number of people who inject drugs receiving opioid substitution therapy, 2015–2017
ANNEX 2
Country 2015 2016 2017
Increase in the number of 
people who inject drugs 
and are receiving opioid 
substitution therapy
Afghanistan 68 270 748 680
Albania 578 605 751 173
Armenia 480 495 501 21
Azerbaijan 168 113 224 56
Bangladesh 595 801 875 280
Belarus 978 869 770 -208
Georgia 1008 4736 7905 6897
India 22 320 23 500 25 400 3080
Iran (Islamic Republic of) 24 662 32 019 21 789 -2873
Kazakhstan 292 423 529 237
Kenya 870 1620 2467 1597
Kyrgyzstan 1234 1203 1232 -2
Malaysia 41 152 54 776 99 481 58 329
Mauritius 4614 4328 4379 -235
Myanmar 10 290 12 474 13 441 3151
Republic of Moldova 468 505 497 29
Senegal 108 155 199 91
Serbia 4336 4995 5404 1068
Seychelles 332 445 155 -177
Tajikistan 572 555 654 82
Ukraine 8512 9214 10189 1677
United Republic of Tanzania 3376 2647 1139 -2237
Viet Nam 43 720 50 358 53 000 9280
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Percentage of people who inject drugs reporting the use of a condom the last time they had 
sexual intercourse, 2011–2017
Country 2011 2012 2013 2014 2015 2016 2017
Armenia 43.7 33.1 41.7 54.9
Belarus 53 41.4 59.5 51.5
Benin 52.9 41.8 30.8 51.8
Bosnia and Herzegovina 32.4 30.8 35.2
Bulgaria 40 59 58 34
China 40.4 43.1 44.8 61.3
Estonia 36.2 38.9 56.1 48.7
Georgia 22.4 34.5 35.6 36.5
Germany 30.6 54.4 41 38
Greece 46.5 47.7 40
Hungary 28.6 20.4 22.1
Japan 35.7 65.9 40
Kazakhstan 47.2 50.6 54 48.9 49.8 47.9
Kyrgyzstan 49.4 39.9 58.8
Latvia 55.6 55.5 66.8 62.5 60
Madagascar 41.3 41.4 41.8
Malaysia 27.8 26.7 20.8 25.7
Mauritius 25 38.2 45.4
Morocco 31.4 30 31.8 28.2 44.6
Nepal 46.5 52.5 48.9
North Macedonia 54.4 46.5 39.8
Philippines 15 13.4 12.9 14.5
Senegal 35.8 38.5 42.7
Serbia 32 30.6 32.4
Tajikistan 39.6 51.9 49.9
Thailand 46.1 49.1 47.2
Tunisia 19.3 29.3 46.7
Ukraine 47.8 54.1 48 43.9
Uzbekistan 42.8 50.1 45.1
Viet Nam 51.9 48.9 41.2 59 38.1 36.5 43.7
  <35         35–70         >70
Source: UNAIDS Global AIDS Monitoring, 2011–2017.
ANNEX 3
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Indicator
Naloxone available 
through community 
distribution (reported by 
national authorities), 2017
Naloxone available  
through community distribution 
(reported by civil society 
representatives and other 
nongovernmental partners), 2017
Naloxone peer 
distribution programme 
operational, 2017
Sources National commitments and policy instrument. Geneva: UNAIDS; 2018.
Stone K, Shirley-Beavan S. 
Global state of harm reduction, 
2018. London: Harm Reduction 
International; 2018.
Afghanistan No Yes Yes
Albania No
Algeria No
Antigua and Barbuda No No
Argentina No No
Armenia No No
Australia Yes
Azerbaijan No
Bahamas No No
Bangladesh No No
Barbados No
Belarus No No
Benin No No
Bolivia (Plurinational State of) No No
Botswana No No
Brazil No
Burundi No No
Cambodia Yes No
Cameroon No
Canada Yes
Central African Republic No No
Chile No No
China Yes Yes
Colombia No No
Comoros No No
Costa Rica No No
Cuba No No
Côte d'Ivoire No No
Czechia No Yes
Denmark Yes
Dominica No No
Dominican Republic No No
El Salvador No No
Equatorial Guinea No No
Estonia Yes
Eswatini No No
Ethiopia No No
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Fiji No No
Gabon No No
Georgia Yes Yes
Germany Yes Yes
Ghana No No
Guatemala Yes
Guinea No No
Haiti No
Honduras No No
Iceland Yes Yes
India Yes
Iran (Islamic Republic of) Yes Yes
Ireland Yes Yes
Italy Yes
Jamaica No No
Kazakhstan No Yes
Kenya No No
Kiribati No No
Kuwait No No
Kyrgyzstan Yes Yes
Lao People's Democratic Republic No No
Latvia No No
Lesotho No
Liberia No No
Libya No No
Lithuania No No
Luxembourg No No
Madagascar No No
Malawi No No
Malaysia Yes
Mali No No
Malta Yes
Marshall Islands Yes No
Mauritius No No
Mexico No No Yes
Micronesia (Federated States of) No No
Montenegro Yes No
Morocco No Yes
Mozambique No No
Myanmar No No
Namibia No No
Nauru No
Nepal No Yes
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New Zealand No
Nicaragua No No
Niger No No
Nigeria No No
Niue No No
Norway Yes
Oman Yes Yes
Pakistan No No
Palau No
Panama No No
Papua New Guinea No No
Paraguay Yes No
Philippines No No
Republic of Moldova Yes Yes
Rwanda No No
Saint Lucia No No
Samoa No No
Saudi Arabia No No
Senegal No No
Serbia No No
Seychelles No No
Sierra Leone No No
South Africa Yes No
South Sudan No No
Spain Yes No
Sri Lanka No No
Sudan No
Suriname No
Syrian Arab Republic No
Tajikistan Yes Yes
Togo No No
Tonga No No
Tunisia No
Tuvalu No No
Uganda No No
Ukraine No No Yes
United Kingdom Yes
United Republic of Tanzania No No
United States Yes
Uruguay No No
Vanuatu No
Venezuela (Bolivarian Republic of) No No
Zambia No No
Zimbabwe No No
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United Nations documents providing guidance and best practices on human rights and drug policy
1. United Nations Development Programme, The International Centre for Human Rights and Drug Policy. International 
guidelines on human rights and drug policy. New York: United Nations Development Programme (UNDP); 2019.
2. Global Commission on HIV and the Law. HIV and the law: risks, rights & health. 2018 supplement. New York: (UNDP); 
2018 (https://hivlawcommission.org/supplement/).
3. United Nations High Commissioner for Human Rights (OHCHR). Implementation of the Joint Commitment to effectively 
Addressing and Countering the World Drug Problem with Regard to Human Rights. A/39/39, September 2018.
4. UNAIDS. Confronting discrimination. Geneva: UNAIDS; 2017 (http://www.unaids.org/en/resources/documents/2017/
confronting-discrimination).
5. UNAIDS. Fast-Track and human rights — advancing human rights in efforts to accelerate the response to HIV. Geneva: 
UNAIDS; 2017.
6. Joint United Nations statement on ending discrimination in health care settings. In: who.int [website]. 27 June 2017. 
UNAIDS; c2019 (http://www.unaids.org/en/resources/documents/2017/ending-discrimination-in-health-care-settings).
7. United Nations Population Fund (UNFPA) Eastern Europe and Central Asia, International Planned Parenthood 
Federation (IPPF) European Network. Health, rights and well-being: a practical tool for HIV and sexual and reproductive 
health programmes with young key populations in eastern Europe and central Asia. UNFPA Eastern Europe and Central 
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